臨床に直結する　感染症診療のエビデンス

出版社： 文光堂
著者：
発行日： 2008-03-06
分野： 臨床医学：内科  >  感染症/AIDS
ISBN： 9784830620119
電子書籍版： 2008-03-06 （第1版第5刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

9,350 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

9,350 円(税込)

購入する

商品紹介

感染症の患者を前に「この検査や治療にエビデンスはあるの？」など臨床現場で実際に生じた疑問に、「簡潔な解説」と「現状を一望できる内容」で答えるエビデンス集。読者が知りたいエビデンスの要点を見やすくまとめた一覧表を満載。各項目の末尾に「現時点における考え方」としてポイントを集約し。現場で求められるエッセンスが一目でわかる。

目次

  • 臨床に直結する　感染症診療のエビデンス

    ―目次―

    1章　感染症診療のエビデンス総論

    2章　感染症の検査（一般）にかかわるエビデンス

    3章　臓器・疾患別 感染症診療にかかわるエビデンス
    ［重症感染症／感染症補助療法のエビデンス］
    ［中枢神経感染症］
    ［呼吸器感染症］
    ［心内膜炎］
    ［カテーテル関連敗血症］
    ［腸管感染症］
    ［腹腔内感染症］
    ［尿路・泌尿器・婦人科系感染症］
    ［骨髄炎］
    ［軟部組織感染］
    ［発熱性好中球減少症，発熱性好中球減少症を含む重症感染症］

    4章　微生物別 感染症診療にかかわるエビデンス
    ［MRSA感染症］
    ［Candida］
    ［aspergillosis］
    ［CD］
    ［結核菌感染症］
    ［ウイルス感染症］

    5章　感染症治療薬にかかわるエビデンス

    6章　Special topics編

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 感染症診療のエビデンス総論

P.2 掲載の参考文献
1) Wood DF. ABC of learning and teaching in medicine : Problem based learning. BMJ 2003 ; 326 : 328-330
 
2) 名郷直樹. EBM超実践法. 東京 : 金原出版, 2002 : 2-8
 
3) Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence-based medicine : what it is and what it isn't. BMJ 1996 ; 312 : 71-72
 
4) Guyatt GH. Evidence-based medicine. ACP Journal Club 1991 ; 114 : A-16
 
5) 名郷直樹. EBM実践ワークブック. 東京 : 南江堂, 1999
 
6) 名郷直樹. 続EBM実践ワークブック. 東京 : 南江堂, 2002
 
7) van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, et al. Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet 1997 ; 349 : 683-687
 
8) The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998 ; 352 : 1877-1881
 
9) Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 2006 ; 368 : 1155-1163
 

2章 感染症の検査 ( 一般 ) にかかわるエビデンス

P.10 掲載の参考文献
1) Zinner SH. Treatment and prevention of infections in immunocompromised hosts. In Gorbach SL et al. Infectious Diseases, 3rd ed. Lippincott Williams & Wilkins, 2003
 
2) Spickett G. Oxford Handbook of Clinical Immunology and Allergy, 2nd ed. USA : Oxford University Press, 2006
 
3) Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996 ; 124 (7) : 633-642
 
4) "Indications to Initiate Antiretroviral Therapy-DHHS Guidelines" http://www.aidsinfo.nih.gov (Last accessed Apr 30, 2007)
 
5) Masur H, Kaplan JE, Holmes KK. U.S. Public Health Service ; Infectious Diseases Society of America Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002 ; 137 (5 Pt 2) : 435-478
 
6) Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001 ; 344 (3) : 168-174
 
7) Blatt SP, Lucey CR, Butzin CA, et al. Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons. JAMA 1993 ; 269 : 622-626
 
8) Bongiovanni M, Gori A, Lepri AC, et al. Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? Clin Infect Dis 2007 ; 45 : 650-653
 
9) Chapter 297 "Primary Immune Deficiency Diseases" In Kasper DL et al. Harrison's Principles of Internal Medicine, 16th ed. McGraw-Hill, 2004
 
10) Clinical Decision Points : course of HIV infection and disease in adults and following effective response to HAART. In Sande MA et al. The Sanford Guide To HIV/AIDS Therapy 2006-2007, 15th ed. Antimicrobial Therapy, 2006
 
11) Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996 ; 156 : 177-188
 
12) Walker UA, Warnatz K. Idiopathic CD4 lymphocytopenia. Curr Opin Rheumatol 2006 ; 18 : 389-395
 
13) Zonios DI, Falloon J, Huang CY, et al. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine 2007 ; 86 : 78-92
 
14) Tashiro T, Yamasaki T, Nagai H, et al. Immunological studies on opportunistic infection and the development of adult T-cell leukemia. Intern Med 1992 ; 31 (9) : 1132-1136
 
15) Mansharamani NG, Balachandran D, Vernovsky I, et al. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000 ; 118 (3) : 712-720
 
16) The ESPRIT Research Group, Fox Z, Antunes F, Davey R, et al. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count > or = 300 cells/microL who were assigned to 7. 5 MIU interleukin-2. HIV Med 2007 ; 8 (2) : 112-123
 
17) Fontaine C, Bonnard P, Mary-Krause M, et al. Pulmonary pneumocystosis in a patient with greater than 500 CD4 cells/microl : a role for IL-2 therapy? AIDS 2006 ; 20 (12) : 1680-1681
 
18) Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia : a retrospective survey of 31 patients. J Pediatr 1999 ; 134 : 589-596
 
19) Liese JG, Wintergerst U, Tympner KD, et al. High-vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992 ; 146 : 335-359
 
20) Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease : A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006 ; 117 : S525-553
 
21) Rose M, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med 2006 ; 73 (6) : 133-144
 
22) Ogi M, Yokoyama H, Tomosugi N, et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephritic syndrome. Am J Kidney Dis 1994 ; 24 : 427-436
 
23) Van Burik JA, Weisdorf D. Infections in recipients of hematopoietic stem cell transplantation. In Mandell GL et al. Principles and Practice of Infectious Diseases 6th ed. Churchill Livingstone, 2004
 
24) Eraklis AJ, Kevy SV, Diamond LK, et al. Hazard of overwhelming infection after splenectomy in childhood. N Engl J Med 1967 ; 276 : 1225-1229
 
25) Gopal V, Bisno AL. Fulminant pneumococcal infections in "normal" aspleic hosts. Arch Intern Med 1977 ; 137 : 1526-1530
 
26) William BM, Thawani N, Sae-Tia S, et al. Hyposplenism : A comprehensive review. Part II : Clinical manifestations, diagnosis, and management. Hematology 2007 ; 12 (2) : 89-98
 
27) Corazza GR, Ginaldi L, Zoli G, et al. Howell-Jolly body counting as a measure of splenic function. A reassessment. Clin Lab Haematol 1990 ; 12 : 269-275
 
28) Suzuki S, Takizawa K, Nakajima Y, et al. CT findings in hepatic and splenic amyloidosis. J Comput Assist Tomogr 1986 ; 10 : 332-334
 
29) Powsner RA, Simms RW, Chudnovsky A, et al. Scintigraphic functional hyposplenism in amyloidosis. J Nucl Med 1998 ; 39 : 221-223
 
30) Morris JT, Kelly WJ. Recurrence of neisserial meningococcemia due to deficiency of terminal complement component. South Med J 1992 ; 85 (10) : 1030-1031
 
31) Bartlett JG, et al. 2005-2006 Medical Management of HIV Infection Johns Hopkins Medicine Health Publishing Business Group, 2006
 
P.15 掲載の参考文献
1) Jaeschke R, Guyatt GH, Sackett DL. User's guides to the medical literature. III. How to use an article about a diagnositic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994 ; 271 : 703-707
 
2) 名郷直樹. 続EBM実践ワークブック. 東京 : 南江堂. 2002 : 90
 
3) Thomas KE, Hasbun R, Jekel J, et al. The diagnostic accuracy of Kernig's sign, Brudzinski's sign, and nuchal rigidity in adults with suspected meningitis. Clin Infect Dis 2002 ; 35 (1) : 46-52
 
4) Tzanakis NE, Efstathiou SP, Danulidis K, et al. A new approach to accurate diagnosis of acute appendicitis. World J Surg 2005 ; 29 (9) : 1151-1156
 
5) Trowbridge RL, Rutkowski NK, Shojania KG. Dose this patient have acute cholecystitis? JAMA 2003 ; 289 (1) : 80-86
 
P.19 掲載の参考文献
1) Reed WW, et al. Sputum Gram's stain in community-acquired pneumoncoccal pneumonia A meta-analysis. West J Med 1996 ; 165 : 197-204
 
2) Rein MF, et al. Accuracy of Gram's stain in identifying pneumococci in sputum. JAMA 1978 ; 239 (25) : 2671-2673
 
3) Boerner DF, et al. The value of the sputum Gram's stain in community-acquired pneumonia. JAMA 1982 ; 247 (5) : 642-645
 
4) Ewig S, et al. Applying sputum as a diagnostic tool in pneumonia : Limited yield, minimal impact on treatment decisions. Chest 2002 ; 121 : 1486-1492
 
5) Sato T, et al. Usefulness of sputum Gram staining in community-acquired pneumonia. 日呼吸会誌 2002 ; 40 (7) : 558-563
 
6) Musher DM, et al. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. CID 2004 ; 39 : 165-169
 
7) Bartlett JG. Diagnostic test for etiologic agents of community-acquired pneumonia. Infect Dis Clin N Am 2004 ; 18 : 809-827
 
P.22 掲載の参考文献
1) Aboelela SW, Saiman L, Stone P, et al. Effectiveness of barrier precautions and surveillance cultures to control transmission of multidrug-resistant organisms : a systematic review of the literature. Am J Infect Control 2006 ; 34 (8) : 484-494
 
2) Wernitz MH, Swidsinski S, Weist K, et al. Effectiveness of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers at hospital admission to prevent hospital-acquired MRSA infections. Clin Microbiol Infect 2005 ; 11 (6) : 457-465
 
P.24 掲載の参考文献
1) Magadia RR, Weinstein MP. Laboratory diagnosis of bacteremia and fungemia. Infect Dis Clin North Am 2001 ; 15 (4) : 1009-1024
 
2) Grill VJ, et al. The clinician and the Microbiology Laboratory. In : Mandell G, Bennett JE, Dolin R ed. Principles And Practice Of Infectious Diseases, 6th ed, Edinburgh : Churchill Livingstone, 2005 : 209-210
 
3) Reller LB, Sexton DJ. Technique of obtaining blood culture for the detection of bacteremia. UpToDate 15. 2 2007 (Cited 2007 May. 5)
 
4) Cockerill FR 3rd. Optimal testing parameters for blood cultures. Clin Infect Dis 2004 ; 38 (12) : 1724-1730
 
5) Mermel LA, Maki DG. Detection of bacteremia in adults : consequences of culturing an inadequate volume of blood. Ann Intern Med 1993 ; 119 (4) : 270-272
 
6) Weinstein MP. Current blood culture methods and systems : clinical concepts, technology, and interpretation of results. Clin Infect Dis 1996 ; 23 (1) : 40-46
 
7) Weinstein MP, et al. The clinical significance of positive blood cultures : A comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983 ; 5 (1) : 35-53
 
8) Washington JA 2nd. Subject review : Blood culture, principles and the techniques. Mayo Clin Proc 1975 ; 50 : 91-98
 
9) Mirrett S, et al. Relevance of the number of positive bottles in determining clinical significance of coagulase-negative staphylococci in blood cultures. J Clin Microbiol 2001 ; 39 (9) : 3279-3281
 
10) Peacock SJ, et al. Positive predictive value of blood cultures growing coagulase-negative staphylococci. Lancet 1995 ; 346 (8968) : 191-192
 
P.27 掲載の参考文献
1) Reller LB. Technique of obtaining blood cultures for the detection of bacteremia. UpToDate(R) 15.1 2007 April 28 (cited 2007 Jan. 10)
 
2) 矢内充他. 血液培養の結果の生かし方-臨床検査医の関わり方の紹介を兼ねて-. 臨床病理 2006 ; 54 : 1059-1065
 
3) Kellogg JA, et al. Clinical laboratory comparison of the 10-ml isolator blood culture system with BACTEC radiometric blood culture media. J Clin Microbiol 1984 ; 20 : 618-623
 
4) Henry NK, et al. Microbiological and clinical evaluation of the ISOLATOR lysis-centrifugation blood culture tube. J Clin Microbiol 1983 ; 17 : 864-869
 
5) Schifman RB, Strand CL. Blood culture contamination date analysis and critique. In : Q-probes. Chigago : College of American Pathologists, 1995 : 1-19
 
6) Mermel LA, et al. Detection of bacteremia in adults : consequences of culturing an inadequate volume of blood. Ann Intern Med 1993 ; 119 : 270-272
 
7) Li J, et al. Effects of volume and periodicity on blood culture. J Clin Microbiol 1994 ; 32 : 2829-2831
 
8) Eyster E, et al. Nosocomial anemia. J Am Med Assoc 1973 ; 223 : 73-74
 
9) Cockerill FR 3rd, et al. Optimal testing parameters for blood cultures. Clin Infect Dis 2004 ; 38 : 1724-1730
 
10) Cohen J, et al. Diagnosis of infection in sepsis : An evidence-based review. Crit Care Med 2004 ; 32 : 466-494
 
11) Lombardi DP, et al. Anaerobic bacteremia : Incidence, patient characteristics, and clinical significance. Am J Med 1992 ; 92 : 53-60
 
12) Murray PR, et al. Critical assessment of blood culture techniques : Analysis of recovery of obligate and facultative anaerobes, strict aerobic bacteria, and fungi in aerobic and anaerobic blood culture bottles. J Clin Microbiol 1992 ; 30 : 1462-1468
 
13) Lassmann B et al. Reemergence of anaerobic bacteremia. Clin Infect Dis 2007 ; 44 : 895-900
 
14) Redondo MC, et al. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis 1995 ; 20 : 1492-1496
 
15) Reimer LG, et al. Update on detection of bacteremia and fungemia. Clin Microbiol Rev 1997 ; 10 : 444-465
 
16) Dietzman DE, et al. Neonatal Escherichia coli septicemia-bacterial counts in blood. J Pediatr 1974 ; 85 : 128-130
 
17) Paisley JW, et al. Pediatric blood culture. Clin Lab Med 1994 ; 14 : 17-30
 
18) Kaditis AG, et al. Yeilds of positive blood culture in pediatric oncology patients by a new method of blood culture collection. Pediatr Infect Dis J 1996 ; 15 : 615-620
 
19) 松本哲哉, 満田年宏訳. CUMITECH血液培養検査ガイドライン, 第1版. 東京 : 医歯薬出版, 2007. 2 : 13-15
 
20) Kellogg JA, et al. Frequency of low-level bacteremia in infants from birth to two months of age. Pediatr Infect Dis J 1997 ; 16 : 381-385
 
21) Kellogg JA, et al. Frequency of low-level bacteremia in children from birth to fifteen years of age. J Clin Microbiol 2000 ; 38 : 2181-2185
 
22) Mandell GL, et al. In : Principles and Practice of Infectious Diseases, 6th ed. USA : Elsevier, 2005 : 3428
 
23) Ilstrup DM, et al. The importance of volume of blood cultured in the detection of bacteremia and fungemia. Diagn Microbial Infect Dis 1983 ; 1 : 107-110
 
P.30 掲載の参考文献
1) Reller LB, et al. Technique of obtaining blood cultures for the detection of bacteremia. UpToDate(R) 2005 August 22, (cited 2006 August)
 
2) Payne DN, et al. An evaluation of the suitability of the European suspension test to reflect in vitro activity of antiseptics against clinically significant organisms. Lett Appl Microbiol 1999 ; 28 (1) : 7-12
 
3) Kutarski PW, et al. To dry or not to dry? An assessment of the possible degradation in efficiency of preoperative skin preparation caused by wiping skin dry. Ann R Coll Surg Engl 1993 ; 75 (3) : 181-185
PubMed
4) Little JR, et al. A randomized trial of povidone-iodine compared with iodine tincture for venipuncture site disinfection : effects on rates of blood culture contamination. Am J Med 1999 ; 107 (2) : 119-125
 
5) Mimoz O, et al. Chlorhexidine compared with povidone-iodine as skin preparation before blood culture. A randomized, controlled trial. Ann Intern Med 1999 ; 131 (11) : 834-837
 
6) Calfee DP, et al. Comparison of four antiseptic preparations for skin in the prevention of contamination of percutaneously drawn blood cultures : a randomized trial. J Clin Microbiol 2002 ; 40 (5) : 1660-1665
 
7) Chaiyakunapruk N, et al. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care : a meta-analysis. Ann Intern Med 2002 ; 136 (11) : 792-801
 
8) O'Grady NP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002 ; 51 (RR-10) : 1-29
 
9) Trautner BW, et al. Skin antisepsis kits containing alcohol and chlorhexidine gluconate or tincture of iodine are associated with low rates of blood culture contamination. Infect Control Hosp Epidemiol 2002 ; 23 (7) : 397-401
PubMed
10) Hibbard JS, et al. Administration of 2% chlorhexidine gluconate in 70% isopropyl alcohol is effective in 30 seconds. Infect Control Hosp Epidemiol 2002 ; 23 (5) : 233-234
 
P.33 掲載の参考文献
1) Benitz WE, Han MY, Madan A, et al. Serial serum C-reactive protein levels in the diagnosis of neonatal infection. Pediatrics 1998 ; 102 (4) : E41
 
2) Pulliam PN, Attia MW, Cronan KM. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics 2001 ; 108 (6) : 1275-1279
 
3) Asseray N, Leconte C, El Kouri D, et al. [CRP in the management of bacterial infections in emergency]. Presse Med 2005 ; 34 (8) : 561-565
 
4) Povoa P, Coelho L, Almeida E, et al. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein : a prospective observational study. Crit Care 2006 ; 10 (2) : R63
PubMed
5) van der Meer V, Neven AK, van den Broek PJ, et al. Diagnostic value of C reactive protein in infections of the lower respiratory tract : systematic review. BMJ 2005 ; 331 (7507) : 26
PubMed
6) Tatara R, Imai H. Serum C-reactive protein in the differential diagnosis of childhood meningitis. Pediatr Int 2000 ; 42 (5) : 541-546
 
7) Povoa P, Coelho L, Almeida E, et al. Pilot study evaluating C-reactive protein levels in the assessment of response to treatment of severe bloodstream infection. Clin Infect Dis 2005 ; 40 (12) : 1855-1857
 
8) Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999 ; 282 (11) : 1061-1066
 
9) Carragee EJ, Kim D, van der Vlugt T, et al. The clinical use of erythrocyte sedimentation rate in pyogenic vertebral osteomyelitis. Spine 1997 ; 22 (18) : 2089-2093
 
10) Unkila-Kallio L, Kallio MJ, Eskola J, et al. Serum C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics 1994 ; 93 (1) : 59-62
 
P.36 掲載の参考文献
1) Yoshida K. Recent advances of serodiagnosis for systemic fungal infections. Nippon Ishinkin Gakkai Zasshi 2006 ; 47 (3) : 135-142
 
2) Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections : validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004 ; 39 (2) : 199-205
 
3) Pazos C, Moragues MD, Quindos G, et al. Diagnostic potential of (1, 3) -beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 2006 ; 23 (4) : 209-215
 
4) Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 --> 3) -beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004 ; 42 (6) : 2733-2741
 
5) Horiguchi Y. The performance of (1, 3) -beta-D-glucan and aspergillus galactomannan measurement for early diagnosis of invasive aspergillosis in patients with hematological diseases. Kansenshogaku Zasshi 2004 ; 78 (7) : 566-573
 
6) Fujita S, Takamura T, Nagahara M, et al. Evaluation of a newly developed down-flow immunoassay for detection of serum mannan antigens in patients with candidaemia. J Med Microbiol 2006 ; 55 (Pt 5) : 537-543
 
7) Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1 -> 3) -beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005 ; 43 (12) : 5957-5962
 
8) Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1 --> 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 ; 41 (5) : 654-659
 
9) Mitsutake K, Miyazaki T, Tashiro T, et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J Clin Microbiol 1996 ; 34 (8) : 1918-1921
 
10) Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay : a meta-analysis. Clin Infect Dis 2006 ; 42 (10) : 1417-1427
 
11) Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003 ; 5 (4) : 158-166
 
12) Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004 ; 42 (10) : 4744-4748
 
13) Mattei D, Rapezzi D, Mordini N, et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004 ; 42 (11) : 5362-5363
 
14) Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005 ; 40 (12) : 1762-1769
 
15) Escuro RS, Jacobs M, Gerson SL, et al. Prospective evaluation of a Candida antigen detection test for invasive candidiasis in immunocompromised adult patients with cancer. Am J Med 1989 ; 87 (6) : 621-627
 
16) Cabezudo I, Pfaller M, Gerarden T, et al. Value of the Cand-Tec Candida antigen assay in the diagnosis and therapy of systemic candidiasis in high-risk patients. Eur J Clin Microbiol Infect Dis 1989 ; 8 (9) : 770-777
 
17) Piens MA, Guyotat D, Archimbaud E, et al. Evaluation of a Candida antigen detection test (Cand-Tec) in the diagnosis of deep candidiasis in neutropenic patients. Eur J Cancer Clin Oncol 1988 ; 24 (10) : 1655-1659
 
18) Fung JC, Donta ST, Tilton RC. Candida detection system (CAND-TEC) to differentiate between Candida albicans colonization and disease. J Clin Microbiol 1986 ; 24 (4) : 542-547
 
19) Pallavicini F, Izzi I, Pennisi MA, et al. Evaluation of the utility of serological tests in the diagnosis of candidemia. Minerva Anestesiol 1999 ; 65 (9) : 637-639
 
20) Sanchez ML, Pfaller MA, Cabezudo I, et al. Diagnosis of disseminated candidiasis in hospitalized patients using the Cand-Tec latex agglutination assay. Mycopathologia 1992 ; 118 (3) : 153-162
 
21) Herent P, Stynen D, Hernando F, et al. Retrospective evaluation of two latex agglutination tests for detection of circulating antigens during invasive candidosis. J Clin Microbiol 1992 ; 30 (8) : 2158-2164
 
22) Phillips P, Dowd A, Jewesson P, et al. Nonvalue of antigen detection immunoassays for diagnosis of candidemia. J Clin Microbiol 1990 ; 28 (10) : 2320-2326
 
23) Yoshida K, Niki Y, Miyashita N, et al. Clinical utility of serum Candida mannan antigen detection kits using ELISA. Kansenshogaku Zasshi 2002 ; 76 (7) : 536-541
 
24) Persat F, Topenot R, Piens MA, et al. Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis. Mycoses 2002 ; 45 (11-12) : 455-460
 
25) Sendid B, Tabouret M, Poirot JL, et al. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies : useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999 ; 37 (5) : 1510-1517
 
26) Kauffman CA. Candidemia in adults. UpToDate 15.2 2007
 
27) Sugar AM. Clinical features and diagnosis of invasive aspergillosis. UpToDate 15.2 2007
 
P.42 掲載の参考文献
1) Roth RR, James WD. Microbiology of the skin : resident flora, ecology, infection. J Am Acad Dermatol 1989 ; 20 (3) 367-390
 
2) Price PB. The bacteriology of normal skin : a new quantitative test applied to a study of the bacterial flora and the disinfectant action of mechanical cleansing. J Infect Dis 1938 ; 63 : 301-318
 
3) Ferreri P, Dajani AS, Wannamaker LW, et al. Natural history of impetigo I : site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest 1972 ; 51 : 2851-2862
 
4) Aly R. Effect of occlusion on microbial population and physical skin conditions. Semin Dermatol 1982 ; 1 : 137-142
 
5) Hartmann AA. Effect of occlusion on resident flora, skin-moisture and skin-pH. Arch Dermatol Res 1983 ; 275 : 251-254
 
6) Lookingbill DP, Miller SH, Knowles RC. Bacteriology of chronic leg ulcers. Arch Dermatol 1978 ; 114 : 1765-1768
 
7) Larson EL, McGinley KJ, Foglia AR, et al. Composition and antimicrobic resistance of skin flora in hospitalized and healthy adults. J Clin Microbiol 1985 ; 23 : 604-608
 
8) Barth JH. Nasal carriage of staphylococci and streptococci. Int J Dermatol 1987 ; 26 : 24-26
PubMed
9) Wartheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005 ; 5 : 751-762
 
10) Wartheim HF, van Kleef M, Vos MC, et al. Nose picking and nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 2006 ; 27 (8) : 863-867
 
11) Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulites in adults. J Clin Microbiol 1988 ; 26 (3) : 401-404
 
12) Lee PC, Turnidge J, McDonald PJ. Fine-needle aspiration biopsy in diagnosis of soft tissue infections. J Clin Microbiol 1985 ; 22 (1) : 80-83
 
13) Hook EW 3rd, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulites in adults. Arch Intern Med 1986 ; 146 (2) : 295-297
 
14) Steer JA, Papini RP, Wilson AP, et al. Quantitative microbiology in the management of burn patients. I. Correlation between quantitative and qualitative burn wound biopsy culture and surface alginate swab culture. Burns 1996 ; 22 (3) : 173-176
 
15) Basak S, Dutta SK, Gupta S, et al. Bacteriology of wound infection : evaluation by surface swab and quantitative full thickness wound biopsy culture. J Indian Med Assoc 1992 ; 90 (2) : 33-34
 
16) Bill TJ, Ratliff CR, Donovan AM, et al. Quantitative swab culture versus tissue biopsy : a comparison in chronic wounds. Ostomy/Wound Management 2001 ; 47 (1) : 34-37
 
17) Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005 ; 41 : 1373-1406
 
18) Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002 ; 346 : 1871-1877
 
P.46 掲載の参考文献
1) Gadde J, Spence M, Wheeler B, et al. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993 ; 270 : 2456-2463
 
2) Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003 ; 349 : 1628-1635
 
3) 社団法人日本化学療法学会臨床試験委員会. 皮内反応特別部会 報告書. 日本化学療法学会雑誌 2003 ; 51 : 497-506
 
4) Sogn DD, Evans R 3rd, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992 ; 152 : 1025-1032
 
5) Salkind AR, Cuddy PG, Foxworth JW. The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 2001 ; 285 : 2498-2505. Review
PubMed
6) Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005 ; 115 : 1048-1057
 
7) Anderson JA. Allergic reactions to drugs and biological agents. JAMA 1992 ; 268 : 2844-2857
 
8) Lin, RY. A perspective on penicillin allergy. Arch Intern Med 1992 ; 152 : 930
PubMed

3章 臓器・疾患別 感染症診療にかかわるエビデンス

P.50 掲載の参考文献
1) Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2000 ; (2) : CD001090
PubMed
2) Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2004 ; (1) : CD001239. Review. PMID : 14973965
 
3) Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis : a systematic review. Clin Infect Dis 2004 ; 39 : 38
PubMed
4) Turgeon AF, Hutton B, Fergusson DA et al. Meta-analysis : intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007 ; 146 (3) : 193-203, PMID : 17283351
 
P.53 掲載の参考文献
1) Bone RC, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College or Chest Physicians/Society of Critical Care Medicine. Chest 1992 ; 101 : 1644-1655
PubMed
2) Weeler AP, et al. Treating patients with severe sepsis. N Engl J Med 1999 ; 340 : 201-214
 
3) Rivers E, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001 ; 345 : 1368-1377
 
4) Zeni F, et al. Anti-inflammatory therapies to treat sepsis and septic shock : A reassessment. Crit Care Med 1997 ; 25 : 1095-1100
 
5) Fisher CJ Jr, et al. Treatment of septic shock with the tumor necrosis factor : Fc fusion protein. N Engl J Med 1996 ; 334 : 1697-1702
 
6) Opal SM, et al. Confirmatory interleukin-1 antagonist trial in severe sepsis : A phase III, randomized, double-blind, placebo-controlled multicenter trial. Crit Care Med 1997 ; 25 : 1115-1124
 
7) Cohen J, et al. Protection from endotoxemia : a rat model for plasmapheresis and specific absorption with polymyxin B. J Infect Dis 1987 ; 155 : 690-695
 
8) Aoki H, et al. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994 ; 167 : 412-417
 
9) Tetta C, et al. Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000 ; 28 : 1526-1533
 
10) Vincent JL, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartilage in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005 ; 23 : 400-405
 
11) Nemoto H, et al. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 2001 ; 19 : 361-368
 
12) Nakamura T, et al. Effect of polymyxin B immobilized fiber hemoperfusion on sepsis induced rhabdomyolysis with acute renal failure. Nephron 2000 ; 86 : 210
PubMed
13) Tani T, et al. Therapeutic apheresis for septic patients with organ dysfunction : hemoperfusion using a polymyxin B immobilized column. Artif Organs 1998 ; 22 : 1038-1044
 
14) Nakamura T, et al. Effects of hemoperfusion on serum cardiac troponin T concentrations using polymyxin B-immobilized fibers in septic patients undergoing hemodialysis. ASAIO J 2002 ; 48 : 41-44
 
15) Kushi H, et al. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 2005 ; 9 : R653-661
 
P.57 掲載の参考文献
1) Tapper ML, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease : a progress report. J Infect Dis 1974 ; 130 (suppl) : S14-23
 
2) Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia : outcome correlations in a prospective study of 200 patients. Am J Med 1989 ; 87 : 540-546
 
3) Mendelson MH, Gurtman A, Szabo S, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994 ; 18 : 886-895
 
4) Siegman-Igra Y, Ravona R, Primerman H, et al. Pseudomonas aeruginosa bacteremia : an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998 ; 2 : 211-215
 
5) Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbial Infect Dis 1998 ; 17 : 701-708
 
6) Leibovici L, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for Gram-negative bacteremia : a prospective, observational study. Antimicrob Agents Chemother 1997 ; 41 : 1127-1133
 
7) Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004 ; 4 (8) : 519-527
 
8) Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005 ; 5 (8) : 192-193
 
9) The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987 ; 317 : 1692-1698
PubMed
10) Lyon MD, et al. In vitro activity of piperacillin, ticarcillin and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1986 ; 30 : 25-30
PubMed
11) Bustamante CI, et al. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990 ; 34 : 1814-1815
 
12) Chandrasekar PH, Crane JR, Bailey EJ. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother 1987 ; 19 : 321-329
 
13) Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia : Retrospective analysis of 410 episodes. Arch Intern Med 1985 ; 145 : 1621-1629
 
14) Vidal F, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia with special emphasis on the influence of antibiotic treatment : analysis of 189 episodes. Arch Intern Med 1996 ; 156 : 2121-2126
 
15) Wu YL, et al. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J Antimicrob Chemother 1999 ; 44 : 389-392
PubMed
16) Bustamante CI, et al. Synergism of the combination of imipenem plus ciprofloxacin and imipenem plus Amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother 1987 ; 31 : 632-634
 
17) Oie S, et al. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1999 ; 44 : 689-691
 
18) Leyland MJ, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992 ; 30 : 843-854
 
19) Dejace P, Klasterski D. Comparative review of combination therapy : Two beta-lactams versus beta-lactam plus aminoglycoside. Am J Med 1986 ; 80 : 29-38
 
P.60 掲載の参考文献
1) Yoshiba M, Inoue K. Evaluation of plasma exchange based on clinical evidence. Jpn J Transfus Med 2002 ; 48 (1) : 9-26
 
2) Fridey JL, Kaplan AA. Indication for therapeutic plasma exchange. UpToDate(R) 15. 1
 
3) Raphael JC, et al. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2002 ; (2) : CD001798
PubMed
4) Busund R, et al. Plasmapheresis in severe sepsis and septic shock : a prospective, randomized, controlled trial. Intensive Care Med 2002 ; 28 : 1434-1439
 
5) Reeves JH, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999 ; 27 (10) : 2096-2104
 
6) Gardlund B, et al. Plasmapheresis in the treatment of primary septic shock in humans. Scand J Infect Dis 1993 ; 25 (6) : 757-761
 
7) Stegmayr BG. Plasma exchange in patients with septic shock including acute renal failure. Blood Purif 1996 ; 14 (1) : 102-108
 
8) Hjorth V, et al. Plasmapheresis as part of the treatment for septic shock. Scand J Infect Dis 2000 ; 32 (5) : 511-514
 
P.62 掲載の参考文献
1) Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987 ; 317 : 653-658
 
2) Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004 : CD002243
PubMed
3) Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis : the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004 ; 141 : 47-56
 
4) Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998 ; 26 : 645-650
 
5) Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock : a prospective, randomized, double-blind, single-center study. Crit Care Med 1999 ; 27 : 723-732
 
6) Chawla K, Kupfer Y, Goldman I. Hydrocortisone reverses refractory septic shock [abstract]. Crit Care Med 1999 ; 27 (1 suppl) : A33
 
7) Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002 ; 288 : 862-871
 
8) Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002 ; 6 : 251-259
 
9) CORTICUS. http://clinicaltrials.gov/ct/show/NCT00147004
 
10) Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004 ; 32 : 858-873
 
11) Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis : a critical appraisal and meta-analysis of the literature. Crit Care Med 1995 ; 23 : 1430-1439
 
12) Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock : a meta-analysis. Crit Care Med 1995 ; 23 : 1294-1303
 
13) Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock : a systematic review and meta-analysis. BMJ 2004 ; 329 : 480
PubMed
P.65 掲載の参考文献
1) Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock : a meta-analysis. Crit Care Med 1995 ; 23 : 1294-1303
 
2) Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis : a critical appraisal and meta-analysis of the literature. Crit Care Med 1995 ; 23 : 1430-1439
 
3) Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis : the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004 ; 141 : 47-56
 
4) Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock : a systematic review and meta-analysis. BMJ 2004 ; 329 ; 480
PubMed
5) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 ; 20 : 864-874
 
6) Sprung CL, Annane D, Keh D, et al, CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008 ; 358 : 111-124
 
P.67 掲載の参考文献
1) Johnson RP. Aseptic meningitis in adults. UpToDate version 15. 1
 
2) Tyler KL. Herpes simplex virus infections of the central nervous system : encephalitis and meningitis, including Mollaret's. Herpes 2004 ; 11 (suppl 2) : 57A-64A
 
3) Shalabi M, Whitley RJ. Recurrent benign lymphocytic meningitis. Clin Infect Dis 2006 ; 43 (9) : 1194-1197
 
4) Mirkhur B, McKenna M. Reccurent herpes simplex type 2 virus (Mollaret) meningitis. J Am Board Fam Pract 2004 ; 17 : 303-305
 
5) http://dynamed101.ebscohost.com/Detail.aspx?id=113810
 
6) Jungmann E. Genital herpes. Clinical Evidence 2006 ; 15 : 1-2
 
P.69 掲載の参考文献
1) Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997 ; 336 (4) : 243-250
 
2) Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991 ; 115 (6) : 428-436
 
3) BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001 ; 56 (suppl 4) : IV1-64
 
4) BTS guidelines for the management of community-acquired pneumonia in adults-2004 update. In : British Thoracic Society Pneumonia Guidelines Committee ; 2004
 
5) Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital : an international derivation and validation study. Thorax 2003 ; 58 (5) : 377-382
 
6) Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006 ; 260 (1) : 93-101
 
7) Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001 ; 163 (7) : 1730-1754
 
8) Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998 ; 158 (4) : 1102-1108
 
9) 日本呼吸器学会. 成人市中肺炎診療ガイドライン ; 2007
 
10) Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 ; 37 (11) : 1405-1433
 
11) Wasson JH, Sox HC, Neff RK, et al. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985 ; 313 (13) : 793-799
 
12) Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005 ; 118 (4) : 384-392
 
13) Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia : reconsidering what is meant by severe pneumonia. Thorax 2006 ; 61 (5) : 419-424
 
14) Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004 ; 59 (5) : 421-427
 
15) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 ; 171 (4) : 388-416
 
16) Auble TY, DM ; Fine, MJ. Community-acquired pneumonia in adults : Risk stratification and the decision to admit. In : Rose B, ed. UpToDate. 15.1 ed. Waltham, MA : UpToDate ; 2007
 
17) Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital : implications for management guidelines. Thorax 2001 ; 56 (4) : 296-301
 
18) Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 ; 44 (suppl 2) : S27
 
P.72 掲載の参考文献
1) Marcos MA, Jimenez de Anta MT, de la Bellacasa JP, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003 ; 21 : 209-214
 
2) Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test : a prospective, controlled clinical evaluation. J Clin Microbiol 2003 ; 41 : 2810-2813
 
3) Roson B, Fernandez-Sabe N, Carratala J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004 ; 38 : 222-226
 
4) Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003 ; 36 : 286-292
 
5) Briones ML, Blanquer J, Ferrando D, et al. Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. Clin Vaccine Immunol 2006 ; 13 : 1092-1097
 
6) Dominguez J, Blanco S, Rodrigo C, et al. Usefulness of urinary antigen detection by an immunochromatographic test for diagnosis of pneumococcal pneumonia in children. J Clin Microbiol 2003 ; 41 : 2161-2163
 
7) Navarro D, Garcia-Maset L, Gimeno C, et al. Performance of the Binax NOW Streptococcus pneumoniae urinary antigen assay for diagnosis of pneumonia in children with underlying pulmonary diseases in the abscence of acute pneumococcal infection. J Clin Microbiol 2004 ; 42 : 4853-4855
 
8) Murdoch DR, Laing RT, Cook JM. The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin Infect Dis 2003 ; 37 : 153-154
 
9) Blazquez RM, Espinosa FJ, Martinez-Toldos CM, et al. Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. Eur J Clin Microbiol Infect Dis 2005 ; 24 : 488-491
 
10) Dirven K, Leven M, Peeters MF, et al. Comparison of three Legionella urinary antigen assays during an outbreak of legionellosis in Belgium. J Med Microbiol 2005 ; 54 : 1213-1216
 
11) Guerrero C, Toldos CM, Yague G, et al. Comparison of diagnostic sensitivities of three assays (Bartels Enzyme Immunoassay [EIA], Biotest EIA, and Binax NOW Immunochromatographic test) for detection of Legionella pneumophila serogroup 1 antigen in urine. J Clin Microbiol 2004 ; 42 : 467-468
 
12) Burnsed LJ, Hicks LA, Smithee LM, et al. A large, travel-associated outbreak of legionellosis among hotel guests : utility of the urine antigen assay in confirming Pontiac fever. Clin Infect Dis 2007 ; 44 : 222-228
 
13) Okada C, Kura F, Wada A, et al. Cross-reactivity and sensitivity of two Legionella urinary antigen kits, Biotest EIA and Binax NOW, to extracted antigens from various serogroups of L. pneumophila and other Legionella species. Microbiol Immunol 2002 ; 46 : 51-54
 
14) 村上日奈子. 尿中レジオネラ抗原検査. モダンメディア 2004 ; 50 : 14-19
 
P.76 掲載の参考文献
1) 平成18年人口動態統計 (確定数) の概況 http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei06/index.html
 
2) 成人市中肺炎診療ガイドライン. 日本呼吸器学会, 2005
 
3) Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007 ; 44 (suppl 2) : S27-72
 
4) Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 ; 37 : 1405-1433
 
5) Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia : a prospective observational study. Chest 2003 ; 123 : 1142-1150
 
6) Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001 ; 95 : 78-82
 
7) Fine MJ, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997 : 336 ; 243
PubMed
8) Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004 ; 39 (2) : 165-169
 
9) Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia : correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003 ; 37 : 230-237
 
10) Corbo J, Friedman B, Bijur P, et al. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004 ; 21 (4) : 446-448
 
11) Campbell SG, Marrie TJ, Anstey R, et al. Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department. Emerg Med J 2003 ; 20 (6) : 521-523
 
12) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 ; 171 : 388-416
 
13) Luna CM, Videla A, Mattera J, et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999 ; 116 : 1075-1084
 
14) Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia : results from a large US database of culture-positive pneumonia. Chest 2005 ; 128 (6) : 3854-3862
 
15) Benenson RS, Kepner AM, Pyle DN 2nd, et al. Selective use of blood cultures in emergency department pneumonia patients. J Emerg Med 2007 ; 33 (1) : 1-8
 
P.80 掲載の参考文献
1) 日本呼吸器学会. 「呼吸器感染症に関するガイドライン」. 成人市中肺炎診療ガイドライン
 
2) Shefet D, Robenshtok E, Paul M, et al. Empirical atypical coverage for inpatients with community- acquired pneumonia. Arch Intern Med 2005 ; 165 : 1992-2000
 
3) Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998 ; 30 : 397-404
 
4) Romanelli G, Cravarezza P, Pozzi A, et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients : a comparative study against standard therapy. J Chemother 2002 ; 14 : 609-617
 
5) Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia : a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995 ; 8 : 1999-2007
 
6) Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007 ; 175 (10) : 1086-1093
 
7) Morris AM. Empirical atypical coverage does not reduce mortality in hospitalised patients with community acquired pneumonia. Evid Based Med 2006 ; 11 (3) : 74
 
8) Shefet D, Robenshtock E, Paul M, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2005 Apr 18 ; (2) : CD 004418
 
9) Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J 2004 ; 24 (1) : 171-181
 
10) Oosterheert JJ, Bonten MJ, Hak E, et al. Severe community-acquired pneumonia : what's in a name? Curr Opin Infect Dis 2003 ; 16 (2) : 153-159
 
11) File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004 ; 125 (5) : 1888-901
 
P.83 掲載の参考文献
1) Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007 ; 44 : S27-72
 
2) MASCOT pneumonia study group. Clinical efficacy of 3days versus 5days of oral amoxicillin for treatment of childhood pneumonia : a multicentre double-blind trial. Lancet 2002 ; 360 : 835-841
 
P.85 掲載の参考文献
1) Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States : an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996 ; 174 : 986-993
 
2) Mufson MA, Krause HE, Schiffman G. Long-term persistence of following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med 1993 ; 173 : 270-275
 
3) Walker FJ, Singleton RJ, Bulkow LR, et al. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 2005 ; 40 : 1730-1735
PubMed
4) Dear K, Holden J, Andrews R, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003 ; 4 : CD000422
PubMed
5) Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994 ; 154 : 2666-2677
 
6) Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000 ; 1 : 1 [Epub 2000 Oct 4]
 
7) Cornu C, Yzebe D, Leophonte P, et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults : a meta-analysis of randomized trials. Vaccine 2001 ; 19 : 4780-4790
 
8) Hutchison BG, Oxman AD, Shannon HS, et al. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999 ; 45 : 2381-2393
 
9) Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine : a systematic review of clinical effectiveness in adults. Vaccine 2002 ; 20 : 2166-2173
 
10) Conaty S, Watson L, Dinnes J, et al. The effectiveness of pneumococcal polysaccharide vaccines in adults : a systematic review of observational studies and comparison with results from randomized controlled trials. Vaccine 2004 ; 22 : 3214-3224
 
11) Fedson DS, Liss C. Precise answers to the wrong question : prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004 ; 22 : 927-946
 
12) Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly : A comparison of meta-analysis. Eur J Epidemiol 2004 ; 19 : 353-363
 
13) Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976 ; 89 : 184-194
 
14) Smit P, Oberholzer D, Hayden-Smith S, et al. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977 ; 238 : 2613-2616
 
15) Riley ID, Tarr PI, Andrews M, et al. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977 ; 1 : 1338-1341
 
16) Austrian R. Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines. Bethesda Md. National Institute of Health Publication DAB-VDP-12-84. Contract No. IA13257. Bethesda, MD. 1980 ; p1-59
 
17) Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986 ; 315 : 1318-1327
 
18) Klastersky J, Mommen P, Cantraine F, et al. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol 1986 ; 22 : 807-813
 
19) Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987 ; 136 : 361-365
 
20) Davis AL, Aranda CP, Schiffman G, et al. Pneumococcal infection and immunologic response to pneu-mococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 1987 ; 92 : 204-212
 
21) Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly : a randomized, single-blind population-based trial. Am J Med 1997 ; 103 : 281-290
 
22) Ortqvist A, Hedlund J, Buman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia I middle-aged and elderly people Swedish Pneumococcal Vaccination Study Group. Lancet 1998 ; 351 : 399-403
 
23) French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults : double-blind, randomized and placebo controlled trial. Lancet 2000 ; 355 : 2106-2111
 
24) Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006 ; 61 : 189-195
 
25) Kaufman P. Pneumonia in old age : active immunization against pneumonia with pneumococcus polysaccharide, results of a 6-year study. Arch Intern Med 1947 ; 79 : 518-531
 
26) Gaillat J, Zmirou D, Mallaret MR, et al. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions. Rev Epidemiol Sante Publique 1985 ; 33 : 437-444
 
27) Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years and older. Vaccine 1999 ; 17 : 2493-2500
 
28) 島田馨. 肺炎球菌ワクチンの概要. 日胸 2001 ; 60 : 873-878
 
29) Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of COPD-2006 Update. Am J Respir Crit Care Med 2007 May 16 [Epub ahead of print]
 
30) Granger R, Walters J, Poole PJ, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive disease. Cochrane Database Syst Rev 2006 ; 4 : CD001390 (～ April 2006)
 
31) CDC : Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR 2002 ; 51 (RR-08) : 1-46
 
32) Shapiro ED, Clemens JD. A Controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984 ; 101 : 325-330
 
33) Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987 ; 83 : 425-430
 
34) Sims RV, Steinmann WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988 ; 108 : 653-657
 
35) Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991 ; 325 : 1453-1460
 
36) Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995 ; 155 : 2336-2340
 
37) Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993 ; 270 : 1826-1831
 
38) Nichol KL, Baken L, Wuorenma J, et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999 ; 159 : 2437-2442
 
39) Christenson B, Lungdbergh P, Hedlund J, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older : a prospective study. Lancet 2001 ; 357 : 1008-1011
 
40) Jackson LA, Neuzil KM, Yu O, et al. Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003 ; 348 : 1747-1755
 
41) Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population : the EVAN-65 study. Clin Infect Dis 2006 ; 43 : 860-868
 
P.88 掲載の参考文献
1) Kopelman TR. Can empiric broad-spectrum antibiotics for ventilator-associated pneumonia be narrowed based on Gram's stain results of bronchoalveolar lavage fluid. Am J Surg 2006 ; 192 : 812
 
2) Davis KA, Eckert MJ, Reed RL 2nd, et al. Ventilator-associated pneumonia in injured patients : do you trust your Gram's stain? J Trauma 2005 ; 58 : 462
 
3) Mentec H, May-Michelangeli L, et al. Blind and bronchoscopic sampling methods in suspected ventilator-associated pneumonia. A multicentre prospective study. Intensive Care Med 2004 ; 30 : 1319
PubMed
4) Mimoz O, Karim A, et al. Gram staining of protected pulmonary specimens in the early diagnosis of ventilator-associated pneumonia. Br J Anaesth 2000 ; 85 : 735
PubMed
5) Blot F, Raynard B, Chachaty E, et al. Value of gram stain examination of lower respiratory tract secretions for early diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 2000 ; 162 : 1731
PubMed
6) Allaouchiche B, Jaumain H, et al. Gram stain of bronchoalveolar lavage fluid in the early diagnosis of ventilator-associated pneumonia. Br J Anaesth 1999 ; 83 : 845
PubMed
P.90 掲載の参考文献
1) Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006 ; 129 : 1210
PubMed
2) Pugol M, et al. Clinical and epidemiological findings in mechanically0ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998 ; 17 (9) : 622-628
 
3) Johnston BL, Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia : acritical review. Semin Respir Infect 1994 ; 9 (3) : 199-206
 
4) Haddadin AS, Fappiano SA, Lipsett PA. Methicillin-resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002 ; 78 ; 385-392
 
5) Hayon J, Figliolini C, Combes A, et al. Role of serial routine microbiologic culture result in the initial management of ventilator-associated pneumonia. Am J Respir Crit Care Med 2002 ; 165 : 41-46
 
6) Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Chest 2000 ; 117 : 177S-181S
 
7) Luna CM, Videla A, Mattera J, et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Am J Respir Crit Care Med 2003 ; 168 ; 173-179
 
8) Baselski VS, Wunderink RG. Bronchoscopic diagnosis of pneumonia. Clin Microbiol Rev 1994 ; 7 : 533
PubMed
9) Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000 ; 132 (8) : 621
PubMed
10) Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006 ; 355 (25) : 2619-2630
 
11) Balthazar AB, Von Nowakonski A, De Capitani EM, et al. Diagnostic investigation of ventilator-associated pneumonia using bronchoalveolar lavage : comparative study with a postmortem lung biopsy. Braz J Med Biol Res 2001 ; 34 (8) : 993-1001
 
12) Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med 1995 ; 152 (6 Pt 1) : 1982-1991
PubMed
13) Corley DE, Kirtland SH, Winterbauer RH, et al. Reproducibility of the histologic diagnosis of pneumonia among a panel of four pathologists : analysis of a gold standard. Chest 1997 ; 112 (2) : 458-465
 
14) Kirtland SH, Corley DE, Winterbauer RH, et al. The diagnosis of ventilator-associated pneumonia : a comparison of histologic, microbiologic, and clinical criteria. Chest 1997 ; 112 (2) : 445-457
 
P.93 掲載の参考文献
1) Ameican Thoracic Society, Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 ; 171 : 388
 
2) Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia : an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000 ; 31 : 383
 
3) Mandell LA, Bartlett JG, Dowell SF, et al. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 ; 37 : 1405
 
4) Mylotte JM. Nursing home-acquired pneumonia : update on treatment options. Drugs Aging 2006 ; 23 : 377-390
 
5) Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 2001 ; 18 : 362-368
 
6) El-Solh AA. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003 ; 167 : 1650-1654
 
7) Muder RR. Pneumonia in residents of long-term care facilities : epidemiology, etiology, management, and prevention. Am J Med 1998 ; 105 : 319-330
 
8) Guay DR. Guidelines for the management of adults with health care-associated pneumonia : implications for nursing facility residents. Consult Pharm 2006 ; 21 (9) : 719-725
 
9) Medina-Walpole AM, McCormick WC. Provider practice patterns in nursing home-acquired pneumonia. J Am Geriatr Soc 1998 ; 46 : 187-192
 
P.95 掲載の参考文献
1) Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care 2002 ; 17 (4) : 240-245
 
2) Cook D, Walter S, Freitag A, et al. Adjudicating ventilator-associated pneumonia in a randomized trial of critically ill patients. J Crit Care 1998 ; 13 (4) : 159-163
 
3) Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998 ; 338 (12) : 791-797
 
4) Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994 ; 120 (8) : 653-662
 
P.97 掲載の参考文献
1) Sintchenko V, et al. Antibiotic therapy of ventilator-associated pneumonia-a reappraisal of rationale in the era of bacterial resistance. Int J Antimicrob Agents 2001 ; 18 (3) : 223-229
 
2) Chastre J, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults : a randomized trial. JAMA 2003 ; 290 (19) : 2588-2598
 
3) Alvarez LF, et al. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001 ; 13 (1) : 70-81
 
4) Singh N, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000 ; 162 (2 pt 1) : 505-511
 
5) Brun-Buisson, C et al. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin : a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998 ; 26 (2) : 346-354
 
6) Damas P, et al. Combination therapy versus monotherapy : a randomized pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia. Crit Care 2006 ; 10 (2) : R52
PubMed
7) Shorr AF, et al. Quinolones for treatment of nosocomial pneumonia : A meta-analysis. Clin Infect Dis 2005 ; 40 : S115-122
 
8) Shorr AF, et al. Levofloxacin for treatment of ventilator-associated pneumonia : a subgroup analysis from a randomized trial. Clin Infect Dis 2005 ; 40 (suppl 2) : S123-129
 
9) The American Thoracic Society & the Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 ; 171 : 388-416
 
10) Schmitt DV, et al. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection 2006 ; 34 : 127-134
 
11) Yakovlev SV, et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis 2006 ; 25 (10) : 633-641
PubMed
P.101 掲載の参考文献
1) Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA Statement : Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007 ; 175 : 367-416
 
2) Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest 1991 ; 99 : 667-669
 
3) Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997 ; 155 : 2041-2046
 
4) Sugihara E, Hirota N, Niizeki T, et al. Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection. J Infect Chemother 2003 ; 9 : 328-332
 
5) Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007 ; 101 : 130-138
 
6) The Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients : five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002 ; 6 : 628-634
 
7) Wallace RJ Jr, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994 ; 149 : 1335-1341
 
8) Field SK, Fisher D, Cowie RL. Mycobacterium avium-intracellulare complex pulmonary disease in patients without HIV infection. Chest 2004 ; 126 : 566-581
 
9) Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999 ; 160 : 866-872
 
10) Kobashi Y, Yoshida K, Miyashita N, et al. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother 2006 ; 12 : 195-202
 
11) Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006 ; 174 : 928-934
 
12) Griffith DE, Brown BA, Murphy DT, et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimen for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998 ; 178 : 121-126
 
13) Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000 ; 30 : 288-292
 
14) Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006 ; 173 : 1283-1289
 
15) Shiraishi Y, Nakajima Y, Takasuna K, et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg 2002 ; 21 : 314-318
 
P.107 掲載の参考文献
1) USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus 2002 (http://aidsinfo.nih.gov/contentfiles/OIpreventionGL.pdf)
 
2) Masur H. Prevention and treatment Pneumocystis pneumonia. N Engl J Med 1992 ; 327 : 1853-1860
 
3) Rodoriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 ; 17 : 770-782
 
4) Hughes WT, Kuhn S, et al. Successful chemiprophylaxis for Pneumocystis carinii pneumonitis.. N Engl J Med 1977 ; 297 : 1419-1426
 
5) Fischl MA, Dickinson GM, Voie LL. Safty and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988 ; 259 : 1185-1189
 
6) Schneider MM, Hoepelman AI, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992 ; 327 : 1836-1841
PubMed
7) Bozzette SA, Finkelstein DM, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995 ; 332 : 693-699
 
P.110 掲載の参考文献
1) CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989 ; 38 (S-5) : 1-9
 
2) Kaplan JE, et al. Guidelines for preventing opportunistic infections among HIV-infected persons-2002 Recommendations of the U.S. Public Health Service and the Infectious Disease Society of America. MMWR 2002 ; 51 (RR-8) : 1-52
 
3) Masur H, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus infected individuals. Ann Intern Med 1989 ; 111 : 223-231
 
4) Phair J, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. NEJM 1990 ; 322 : 161-165
 
5) Kaplan JE, et al. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States : reassessment of indications for chemoprophylaxis. J Infect Dis 1998 ; 178 : 1126-1132
 
6) Stansell JD, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Am J Respir Crit Care 1997 ; 155 : 60-66
 
7) Mansharamani NG, et al. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000 ; 118 : 712-720
 
P.113 掲載の参考文献
1) 尾内一信, 他. 日本におけるChlamydia pneumoniaeとその他のクラミジアの年齢別抗体保有率の検討. 感染症学雑誌 1991 ; 65 : 19-25
 
2) Vikerfors TG, Brodin M, Grandien L, et al. Detection of specific IgM antibodies for the diagnosis of Mycoplasma pneumoniae infections : a clinical evaluation. Scand J Infect Dis 1988 ; 20 : 601-610
 
3) Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America ; American Thoracic Society. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 ; 44 : S27-72
 
4) 日本呼吸器学会市中肺炎診療ガイドライン作成委員会. 成人市中肺炎診療ガイドライン 2007 : 22
 
5) Dowell SF, Peeling RW, Boman J, et al. C. pneumoniae Workshop Participants. Standardizing Chlamydia pneumoniae assays : recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001 ; 33 : 492-503
 
6) Mandell LA, Bartlett JG, Dowell SF, et al. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 ; 37 : 1405-1433
 
7) Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae : current status of diagnostic methods. Clin Infect Dis 2007 ; 44 : 568-576
 
8) Hammerschlag MR. Chlamydia pneumoniae and the lung. Eur Respir J 2000 ; 16 : 1001-1007
 
9) Littman AJ, Jackson LA, White E, et al. Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglubulin A and G antibody titers. Clin Diagn Lab Immunol 2004 ; 11 : 615-617
 
10) Kutlin A, Tsumura N, Emre U, et al. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection. Clin Diagn Lab Immunol 1997 ; 4 : 213-216
 
11) Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004 ; 17 : 697-728
 
12) Alexander TS, Gray LD, Kraft JA, et al. Performance of Meridian ImmunoCard Mycoplasma test in a multicenter clinical trial. J Clin Microbiol 1996 ; 34 : 1180-1183
 
13) Beersma MF, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglubulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol 2005 ; 43 : 2277-2285
 
14) Ozaki T, Nishimura N, Ahn J, et al. Utility of a rapid diagnosis kit for Mycoplasma pneumoniae pneumonia in children, and the antimicrobial susceptibility of the isolates. J Infect Chemother 2007 ; 13 : 204-207
 
P.117 掲載の参考文献
1) Satomura K, et al. Prevention of upper respiratory tract infections by gargling : a randomized trial. Am J Prev Med 2005 ; 29 (4) : 302-307
 
2) 名郷直樹. 続EBM実践ワークブック, 東京 : 南江堂, 2002
 
P.121 掲載の参考文献
1) Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev 2005 ; (3) : CD000247
PubMed
2) Fahey T, Stocks N, Thomas T. Systematic review of the treatment of upper respiratory tract infection. Arch Dis Child 1998 ; 79 : 225-230
 
3) Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults : background, specific aims, and methods. Ann Intern Med 2001 ; 134 (6) : 479-486
 
4) Dowell SF, Schwartz B. Resistant pneumococci : protecting patients through judicious use of antibiotics. Am Fam Physician 1997 ; 55 (5) : 1647-1654, 1657-1658
 
5) Goossens H, Ferech M, Vander Stichele R, et al. ESAC Project Group. : Outpatient antibiotic use in Europe and association with resistance : a cross-national database study. Lancet 2005 ; 365 (9459) : 579-587
 
6) Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997 ; 337 (7) : 441-446
 
7) Fendrick AM, Monto AS, Nightengale B, et al. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003 ; 163 (4) : 487-494
 
P.123 掲載の参考文献
1) Subcommittee on Management of acute otitis media. Diagnosis and management of acute otitis media. Pediatrics 2004 ; 113 (5) : 1451-1465
 
2) Del Mar C, et al. Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis. BMJ 1997 ; 314 : 1526-1532
 
3) Glasziou P, et al. Antibiotics for acute otitis media in children. Cochrane Database 2004 ; (1) Review
PubMed
4) Damoiseaux RA, et al. Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years. BMJ 2000 ; 320 : 350-354
 
5) Little P, et al. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001 ; 322 (7282) : 336-342
 
6) Spiro DM, et al. Wait-and-see prescription for the treatment of acute otitis media : a randomized controlled trial. JAMA 2006 ; 296 (10) : 1235-1241
 
7) van Buchem FD, et al. Acute otitis media : a new treatment strategy. Br Med J 1985 ; 290 (6474) : 1033-1037
 
8) Klein JO, et al. Epidemiology, pathogenesis, clinical manifestations, and complications of acute otitis media. UpToDate(R) 15.1
 
9) Klein JO, et al. Treatment of acute otitis media. UpToDate(R) 15.1
 
P.125 掲載の参考文献
1) Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults : Background. Ann Intern Med 2001 ; 134 : 498-505
 
2) Williams JW Jr, Simel DL. Does this patient have sinusitis? Diagnosing acute sinusitis by history and physical examination. JAMA 1993 ; 270 : 1242-1246
 
3) Hansen JG, Schmidt H, Rosborg J, et al. Predicting acute maxillary sinusitis in a general practice population. BMJ 1995 ; 311 : 233-236
 
4) Gwaltney JM Jr, Wiesinger BA, Patrie JT. Acute community-acquired bacterial sinusitis : the value of antimicrobial treatment and the natural history. Clin Infect Dis 2004 ; 38 : 227-233
 
5) Ioannidis JP, Lau J. Technical report : evidence for the diagnosis and treatment of acute uncomplicated sinusitis in children : a systematic overview. Pediatrics 2001 ; 108 (3) : E57
PubMed
6) Williams JW Jr. Antibiotics for acute maxillary sinusitis. Cochrane Database of Systematic Reviews 2007 Issue 2
 
P.127 掲載の参考文献
1) BMJ Publishing Group Ltd 2006. Bronchitis (acute). Clinical Evidence 2006 ; 15 : 1996-2005
 
2) Wenzel RP, et al. Acute bronchitis. N Engl J Med 2006 ; 355 : 2125-2130
 
3) Macfarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001 ; 56 : 109-114
 
4) Smucny J, Fahey T, Becker L, et al. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2004 18 ; (4) : CD000245
 
5) Orr PH, Scherer K, Macdonald A, et al. Randomized placebo-controlled trials of antibiotics for acute bronchitis : a critical review of the literature. J Fam Pract 1993 ; 36 (5) : 507-512
 
6) Smucny JJ, Becker LA, Glazier RH, et al. Are antibiotics effective treatment for acute bronchitis? A meta-analysis. J Fam Pract 1998 ; 47 (6) : 453-460
 
7) Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults. BMJ 1998 ; 316 : 906-910
 
8) Bent S, Saint S, Vittinghoff E, et al. Antibiotics in acute bronchitis : a meta-analysis. Am J Med 1999 ; 107 : 62-67
 
9) Brickfield FX, Carter WH, Johnson RE. Erythromycin in the treatment of acute bronchitis in a community practice. J Fam Pract 1986 ; 23 : 119-122
 
10) Dunlay J, Reinhardt R, Roi LD. A placebo-controlled, double-blind trial of erythromycin in adults with acute bronchitis. J Fam Pract 1987 ; 25 : 137-141
 
11) Evans AT, Husain S, Durairaj L, et al. Azithromycin for acute bronchitis : a randomised, double-blind, controlled trial. Lancet 2002 ; 359 : 1648-1654
 
12) Franks P, Gleiner JA. The treatment of acute bronchitis with trimethoprim and sulfamethoxazole. J Fam Pract 1984 ; 19 : 185-190
 
13) Howie JGR, Clark GA. Double-blind trial of early demethychlortetracycline in minor respiratory illness in general practice. Lancet 1970 ; 28 (2 (7683)) : 1099-1102 Links
 
14) Hueston WJ. Albuterol delivered by metered-dose inhaler to treat acute bronchitis. J Fam Pract 1994 ; 39 (5) : 437-440
 
15) Kaiser L, Lew D, Hirschel B, et al. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet 1996 ; 347 : 1507-1510
 
16) King DE, Williams WC, Bishop L, et al. Effectiveness of erythromycin in the treatment of acute bronchitis. J Fam Pract 1996 ; 42 : 601-605
 
17) Matthys H, de Mey C, Carls C, et al. Efficacy and tolerability of Myrtol standardised in Acute Bronchitis. Arzneimittel-Forschung 2000 ; 50 : 700-711
 
18) Scherl ER, Riegler SL, Cooper JK. Doxycycline in acute bronchitis : a randomized double-blind trial. J Ky Med Assoc 1987 ; 85 : 539-541
 
19) Stott NCH, West RW. Randomised controlled trial of antibiotics in patients with cough and purulent sputum. Br Med J 1976 ; 2 : 556-559
 
20) Verheij TJM, Hermans J, Mulder JD. Effects of doxycycline in patients with acute cough and purulent sputum : a double blind placebo controlled trial. Br J Gen Pract 1994 ; 44 : 400-404
 
21) Williamson HA. A randomized controlled trial of doxycycline in the treatment of acute bronchitis. J Fam Pract 1984 ; 19 : 481-486
 
P.132 掲載の参考文献
1) Smith S, Demicheli V, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No. : CD004879. DOI : 10.1002/14651858.CD004879.pub2.
 
2) Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No. : CD001269. DOI : 10.1002/14651858.CD001269.pub3.
 
3) Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No. : CD004876. DOI : 10.1002/14651858.CD004876.pub2.
 
4) Poole PJ, Chacko E, Wood-Baker RWB, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No. : CD002733. DOI : 10.1002/14651858.CD002733.pub2.
 
5) Cates CJ, Jefferson TO, Bara AI, et al. Vaccines for preventing influenza in people with asthma. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No. : CD000364. DOI : 10.1002/14651858.CD000364.pub2.
 
6) Thomas RE, Jefferson T, Demicheli V, et al. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No. : CD005187. DOI : 10.1002/14651858.CD005187.pub2.
 
7) Gurfinkel EP, et al. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions : the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002 ; 105 (18) : 2143-2147
 
8) 名郷直樹. 続EBM実践ワークブック, 東京 : 南江堂, 2002
 
9) 名郷直樹. EBMキーワード, 東京 : 中山書店, 2005
 
10) 神谷齊, 他. インフルエンザワクチンの効果に関する研究. 厚生科学研究費補助金先端的厚生科学研究分野新興・再興感染症研究事業, 1999
 
11) 神谷齋, 他. 乳幼児に対するインフルエンザワクチンの効果に関する研究. 厚生科学研究費補助金先端的厚生科学研究分野新興・再興感染症研究事業, 2000
 
P.136 掲載の参考文献
1) http://idsc.nih.go.jp/disease/influenza/index.html
 
2) Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults : systematic review. Lancet 2006 ; 367 : 303
PubMed
3) Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B : systematic review and meta-analyses of randomised controlled trials. BMJ 2003 ; 326 : 1235
 
4) Matheson NJ, Symmonds-Abrahams, M, Sheikh, A, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007 ; (1) : CD002744
 
5) Hayden F, Atmar R, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999 ; 341 : 1336
PubMed
6) The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998 ; 352 : 1877
 
7) Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza : a randomised controlled trial. Lancet 2000 ; 355 : 1845-1850
 
8) Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B : a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006 ; 43 : 439
 
9) Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007 ; 44 : 197
PubMed
10) Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003 ; 163 : 1667
PubMed
11) Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005 ; 24 : 931
PubMed
12) Zachary K. Antiviral drugs for the treatment of influenza in adults. UpToDate 15.3 2007 July 16 (cited 2007 August)
 
13) Hall C. Antiviral drugs for the prevention and treatment of influenza in children. UpToDate 15.3 2007 July 16 (cited 2007 August)
 
P.140 掲載の参考文献
1) Amantadine and rimantadine for influenza A in adults. : The Cochrane Library. http://www.thecochranelibrary.com
 
2) Amantadine and rimantadine for influenza A in children and the elderly (protocol only) : The Cochrane Library. http://www.thecochranelibrary.com
 
3) Neuraminidase inhibitors for preventing and treating influenza in children : The Cochrane Library. http://www.thecochranelibrary.com
 
4) Neuraminidase inhibitors for preventing and treating influenza in healthy adults : The Cochrane Library. http://www.thecochranelibrary.com
 
5) Chinese medicinal herbs for influenza : The Cochrane Library. http://www.thecochranelibrary.com
 
6) Homoeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes : The Cochrane Library. http://www.thecochranelibrary.com
 
7) Influenza vaccination for healthcare workers who work with the elderly : The Cochrane Library. http://www.thecochranelibrary.com
 
8) Vaccines for preventing influenza in healthy adults : The Cochrane Library. http://www.thecochranelibrary.com
 
9) Vaccines for preventing influenza in healthy children : The Cochrane Library. http://www.thecochranelibrary.com
 
10) Vaccines for preventing influenza in the elderly : The Cochrane Library. http://www.thecochranelibrary.com
 
11) 厚生労働省 インフルエンザ脳症研究班. インフルエンザ脳症ガイドライン, 2005年11月
 
12) Kawashima H, et al. Efficacy of plasma exchange and methylprednisolone pulse therapy on influenza-associated encephalopathy. J Infect 2005 ; 51 (2) : E53-56
 
13) Sugaya N, et al. Amantadine therapy for influenza type A-associated encephalopathy. Pediatr Infect Dis J 1999 ; 18 (8) : 734
PubMed
14) Gesky JM, et al. Amantadine penetration into cerebrospinal fluid of a child with influenza A encephalitis. Pediatr Infect Dis J 2004 ; 23 (3) : 270-272
 
15) Straumanis JP, et al. Influenza B infection associated with encephalitis : treatment with oseltamivir. Pediatr Infect Dis J 2002 ; 21 (2) : 173-175
 
16) Munakata M, et al. Combined therapy with hypothermia and anticytokine agents with influenza A encephalopathy. Brain Dev 2000 ; 22 (6) : 373-377
 
P.142 掲載の参考文献
1) Larbalestier RI, Kinchla NM, Aranki SF, et al. Acute bacterial endocarditis : optimizing surgical results. Circulation 1992 ; 86 : II 68
 
2) Moon MR, Stinson EB, Miller DC. Surgical treatment of endocarditis. Prog Cardiovasc Dis 1997 ; 40 : 239
PubMed
3) Di Salvo G, Habib G, Pergola V, et al. Echocardiography predicts embolic events in infectice endocarditis. J Am Coll Cardiol 2001 ; 37 : 1069-1076
 
4) Rohmann S, Erbel R, Gorge G, et al. Clinical relevance of vegetation localization by transesophageal echocardiography in infective endocarditis. Eur Heart J ; 1992 : 13 : 446-452
 
5) Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis Journal of infection 2005 ; 51 : 230-247
 
6) Olaison L, Pettersson G. Current best practices and guidelines indications for surgical intervention in infective endocarditis. Infect Dis Clin North Am 2002 ; 16 : 453-475
 
7) D'Udekem Y, David TE, Feindel CM, et al. Long-term results of surgery for active infective endocarditis. Eur J Cardiothoracic Surg 1997 ; 11 : 46-52
 
8) John MD, Hibberd PL, Karchmer AW et al. Staphylococcus aureus prosthetic valve endocarditis : optimal management and risk factors for death. Clin infect Dis 1998 ; 26 : 1302-1309
 
9) Habib G, Tribouilloy F, Thuny R, et al. Prosthetic valve endocarditis : who needs surgery? A multicentre study f 104 cases. Heart 2005 ; 91 : 954-959
 
P.145 掲載の参考文献
1) Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation 1997 ; 96 : 358-366
 
2) 日本循環器学会. 感染性心内膜炎の予防と治療に関するガイドライン Circulation Journal 2003 ; 67 (suppl IV) : 1062-1071
 
3) Devereux RB, Frary CJ, Kramer-Fox R, et al. Cost-effectiveness of infective endocarditis prophylaxis for mitral valve prolapse with or without a mitral regurgitant murmur. Am J Cardiol 1994 ; 74 : 1024-1029
PubMed
4) Devereux RB, Kramer-Fox R, Kligfield P. Mitral valve prolapse : causes, clinical manifestation, and management. Ann Intern Med 1989 ; 111 : 305-317
 
5) Berney P, Francioli P. Successful prophylaxis of experimental streptococcal endocarditis with single-dose amoxicillin administered after bacterial challenge. J Infect Dis 1990 ; 161 : 281-285
 
6) Botoman V, Surawicz C. Bacteremia with gastrointestinal endoscopic procedures. Gastrointest Endosc 1986 ; 32 : 342-346
 
7) Sullivan N, Sutter V, Mims M, et al. Clinical aspects of bacteremia after manipulation of the genitourinary tract. J Infect Dis 1973 ; 127 : 49-55
 
8) Durack DT. Prevention of infective endocarditis. N Engl J Med 1995 ; 332 : 38-44
 
9) Jarvis WR, Edwards JR, Culver DH, et al. Nosocominal infection rates in adult and pediatric intensive care units in the United States. National Nosocominal Infection Surveillance System. Am J Med 1991 ; 91 : 185S-191S
 
10) Millar BC, Moore JE. Antibiotic prophylaxis, body piercing and infective endocarditis. Journal of Antimicrobial Chemotherapy 2004 ; 53 : 123-126
 
11) Prevention of Infective Endocarditis Guideline from the American Heart Association. Circulation 2007 ; 116 : 1736-1754 (originally published online Apr 19, 2007)
 
P.148 掲載の参考文献
1) O'Grady NP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002 ; 51 (RR-10) : 1-29
 
2) Tagalakis V, et al. The Epidemiology of Peripheral Vein Infusion Thrombophlebitis : A Critical Review. Am J Med 2002 ; 113 : 146-151
 
3) Bregenzer T, et al. Is Routine replacement of peripheral intravenous catheter necessary? Arch Intern Med 1998 ; 158 : 151-156
 
4) Maki DG, et al. The risk of bloodstream infection in adults with different intravascular devices : a systematic review of 200 published prospective studies. Mayo Clin Proc 2006 ; 81 : 1159-1171
 
5) Maki DG, et al. Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial. Ann Intern Med 1991 ; 115 : 845-854
 
6) Soifer NE, et al. Prevention of Peripheral Venous Catheter Complications With an Intravenous Therapy Team A Randomized Controlled Trial. Arch Intern Med 1998 ; 158 : 473-477
 
7) Malach T, et al. Prospective surveillance of phlebitis associated with peripheral intravenous catheters. Am J Infect Control 2006 ; 34 : 308-312
 
8) Couzigou C, et al. Short peripheral venous catheters : effect of evidence-based guidelines on insertion, maintenance and outcomes in a university hospital. J Hosp Infect 2005 ; 59 : 197-204
 
9) Lai KK. Safety of prolonging peripheral cannula and i.v. tubing use from 72 hours to 96 hours. Am J Infect Control 1998 ; 26 : 66-70
 
P.150 掲載の参考文献
1) Safdar N. Meta-analysis : methods for diagnosing intravascular device-related blood stream infection. Ann Intern Med 2005 ; 142 (6) : 451-466
 
2) Band JD. Diagnosis of central venous catheter-related bloodstream infections. UpToDate(R) 15.1
 
3) O'Grady. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2002 ; 51 : 1
 
4) Clinical utility of blood cultures drawn from indwelling central venous catheter in hospitalized patients with cancer. Ann Intern Med 1999 ; 131 (9) : 641-647
 
5) Ultrastructual analysis of indwelling vascular catheters : a quantitative relationship between luminalcolonization and duration of placement. J Infect Dis 1993 ; 168 (2) : 400-407
 
6) Raad I, Hanna HA, Alakech B, et al. Differential time to positivity : A useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004 ; 140 : 18-25
 
7) 2001 guideline for the management of intravascular catheter-related infections. Clin Infect Dis 2001 ; 32 : 1249
PubMed
P.153 掲載の参考文献
1) Band JD. Treatment of central venous catheter-related infections. UpToDate 15.1 2007 January 3, 2007
 
2) Mermal LA, Farr BM, Sherertz RJ. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001 ; 32 : 1249-1272
 
3) Raad I, Davis S, Khan A, et al. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococccal bacteremia. Infect Control Hosp Epidemiol 1992 ; 13 : 215-221
 
4) Coyle VM, McMullan R, Morris TC, et al. Catheter-related bloodstream infection in adult haematology patients : catheter removal practice and outcome. J Hosp Infect 2004 ; 57 : 325-331
 
5) Rijnders BJ, Peetermans WE, Verwaest C, et al. Watchful waiting versus immediate catheter removal in ICU patients with suspected catheter-related infection : a randomized trial. Intensive Care Med 2004 ; 30 : 1073-1080
 
6) Rodriguez-Bano J. Selection of empiric therapy in patients with catheter-related infections. Clin Microbiol Infect 2002 ; 8 : 275-281
 
7) Hanna H, Afif C, Alakech B, et al. Central venous catheter-related bacteremia due to gram-negative bacilli : significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 2004 ; 25 : 646-649
 
8) Kim SH, Kang CI, Kim HB, et al. Outcomes of Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003 ; 24 : 897-904
 
P.157 掲載の参考文献
1) Maki DG, et al. The risk of bloodstream infection in adults with different intravascular devices : A systematic review of 200 published prospective studies. Mayo Clin Proc 2006 ; 81 : 1159-1171
 
2) Leonardo L, et al. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Critical Care 2005 ; 9 : R631-635
 
3) Wisplinghoff H, et al. Nosocomial bloodstream infections in US hospitals : Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 ; 39 : 309-317
 
4) Mermel LM, et al. Guidelines for the Management of Intravascular Catheter-Related Infections. Clin Infect Dis 2001 ; 32 : 1249-1272
 
5) Robert J, et al. Three-year experience with sonicated vascular catheter cultures in a clinical microbilology laboratory. J Clin Microbiol 1990 ; 28 : 76-82
 
6) Bouza E, et al. Catheter-related infections : diagnosis and intravascular treatment. Clin Microbiol Infect 2002 ; 8 : 265-274
 
7) Moonens S, et al. Usefulness of gram staining of blood collected from total parenteral nutrition catheter for rapid diagnosis of catheter-related sepsis. J Clin Microbiol 1994 ; 32 : 1578-1579
 
8) Leon M, et al. Diagnostic value of Gram staining of peri-catheter skin and the connection in the prediction of intravascular-catheter-related bacteremia. Enferm Infecc Microbiol Clin 1998 ; 16 : 214-218
 
9) McGeer A, et al. Improving our ability to diagnose infections associated with central venous catheters : value of Gram's staining and culture of entry site swabs. CMAJ 1987 ; 137 : 1009-1015
 
10) Jesus R, et al. Selection of empiric therapy in patients with catheter-related infections. Clin Microbiol Infect 2002 ; 8 : 275-281
 
11) Smith SR, et al. Randomized Prospective Study Comparing Vancomycin with Teicoplanin in the Treatment of Infections Associated with Hickman Catheters. Antimicrob Agents Chemother 1989 ; 33 : 1193-1197
 
12) Rolston KV, et al. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 1994 ; 169 : 350-355
 
13) Wunderink RG, et al. Linezolid vs vancomycin : analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003 ; 124 : 1789-1797
 
14) Carratala J, The antibiotic-lock technique for therapy of 'highly needed' infected catheters. Clin Microbiol Infect 2002 ; 8 : 282-289
 
15) Bart J, et al. Treatment of long-term intravascular catheter-related bacteremia with antibiotic lock : randomized, placebo-controlled trial. J Antimicrob Chemother 2005 ; 55 : 90-94
 
16) Fortun J, et al. Treatment of long-term intravascular catheter-related bacteremia with antibiotic-lock therapy. J Antimicrob Chemother 2006 ; 58 : 816-821
 
P.160 掲載の参考文献
1) Pittet D, Li N, Woolson RF, et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections : a 6-year validated, population-based model. Clin Infect Dis 1997 ; 24 : 1068-1078
 
2) Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals : analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 ; 39 : 309-317
 
3) Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000 ; 118 : 146-155
 
4) Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained : a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005 ; 49 : 3640-3645
 
5) Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia : a multi-institutional study. Clin Infect Dis 2006 ; 43 : 25-31
 
6) Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001 ; 32 : 1249-1272
 
7) Rodriguez-Bano J. Selection of empiric therapy in patients with catheter-related infections. Clin Microbiol Infect 2002 ; 8 : 275-281
 
8) Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994 ; 331 : 1325-1330
 
9) Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002 ; 35 : 627-630
 
10) Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 ; 347 : 2020-2029
 
11) Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis : a phase III randomised double-blind trial. Lancet 2007 ; 369 : 1519-1527
 
12) Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004 ; 38 : 161-189
 
P.162 掲載の参考文献
1) Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988 ; 2 (8626-8627) : 1437-1442
 
2) Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence : a review. Gastroenterology 1996 ; 110 (4) : 1244-1252
 
3) Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998 ; 93 (9) : 1409-1415
 
4) Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial. JAMA 2004 ; 291 (2) : 187-194
 
5) Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997 ; 6 (8) : 639-642
 
6) Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I (E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001 ; 19 (22) : 4245-4251
 
7) Grunberger B, Wohrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006 ; 24 (9) : 1370-1375
 
8) Sato R, Murakami K, Watanabe K, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med 2004 ; 164 (17) : 1904-1907
 
9) Suzuki T, Matsushima M, Masui A, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol 2005 ; 100 (6) : 1265-1270
 
10) Froehlich F, Gonvers JJ, Wietlisbach V, et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol 2001 ; 96 (8) : 2329-2336
PubMed
11) Schaeverbeke T, Broutet N, Zerbib F, et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. Am J Gastroenterol 2005 ; 100 (12) : 2637-2643
 
12) Giral A, Ozdogan O, Celikel CA, et al. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. J Gastroenterol Hepatol 2004 ; 19 (7) : 773-777
 
13) Ohkusa T, Takashimizu I, Fujiki K, et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann Intern Med 1998 ; 129 (9) : 712-715
 
14) Hong SS, Jung HY, Choi KD, et al. A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication. Helicobacter 2006 ; 11 (6) : 569-573
 
15) Satoh K. Indications for Helicobacter pylori eradication therapy and first-line therapy regimen in Japan : recommendation by the Japanese Society for Helicobacter Research. J Gastroenterol 2002 ; 37 (suppl 13) : 34-38
 
16) Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998 ; 93 (12) : 2330-2338
 
17) Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 ; 16 (2) : 167-180
 
18) Peura DA. Treatment regimens for Helicobacter pylori. In : UpToDate ; 2007
 
19) Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992 ; 87 (12) : 1716-1727
 
20) Lamouliatte H, Cayla R, Zerbib F, et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection : results of a prospective randomized open study. Am J Gastroenterol 1998 ; 93 (9) : 1531-1534
 
21) Sullivan B, Coyle W, Nemec R, et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol 2002 ; 97 (10) : 2536-2539
 
22) Lara LF, Cisneros G, Gurney M, et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003 ; 163 (17) : 2079-2084
 
23) Vakil N, Connor J. Helicobacter pylori eradication : equivalence trials and the optimal duration of therapy. Am J Gastroenterol 2005 ; 100 (8) : 1702-1703
 
24) Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006 ; 101 (9) : 1985-1990
 
25) Houben MH, van de Beek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999 ; 13 (8) : 1047-1055
 
26) Fallone CA. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 2000 ; 14 (10) : 879-882
 
27) Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol 2006 ; 47 (5) : 337-349
 
P.166 掲載の参考文献
1) Chitkara YK, et al. Development and implementation of cost-effective guidelines in the laboratory investigation of diarrhea in a community hospital. Arch Intern Med 1996 ; 156 (7) : 1445-1448
 
2) McFarland LV. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am J Infect Control 1995 ; 23 (10) : 295-305
 
3) Mishu B, et al. Outbreaks of Salmonella enteritidis infection in the United States, 1985-1991. J Infect Dis 1994 ; 169 (3) : 547-552
 
4) L'Ecuyer PB, et al. Nosocomial outbreak of gastroenteritis due to Salmonella senftenberg. Clin Infect Dis 1996 ; 23 (10) : 734-742
 
5) Wall PG, et al. Outbreaks of salmonellosis in hospitals in England and Wales : 1992-1994. J Hosp Infect 1996 ; 33 : 181-190
 
6) McFarland LV. Diarrhea acquired in the hospital. Gastroenterol Clin North Am 1993 ; 22 (3) : 563-577
 
7) Fan K, et al. Application of rejection criteria for stool cultures for bacterial enteric pathogens. J Clin Microbiol 1993 ; 31 (8) : 2233-2235
 
8) Valenstein P, et al. The use and abuse of routine stool microbiology. Arch Pathol Lab Med 1996 ; 120 (2) : 206-211
 
9) Rohner P, et al. Etiological agents of infectious diarrhea : Implications for requests for microbial culture. J Clin Microbiol 1997 ; 35 (6) : 1427-1432
 
10) Bauer TM, et al. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. JAMA 2001 ; 285 (3) : 313-319
 
11) Siegel DL, et al. Inappropriate testing for diarrheal disease in the hospital. JAMA 1990 ; 263 (7) : 979-982
 
P.169 掲載の参考文献
1) Guerrant RL, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001 ; 32 : 331-351
 
2) 2005年 感染性腸炎研究会資料
 
3) Rohner P, et al. Etiological agents of infectious diarrhea : implications for request for microbial culture. J Clin Microbiol 1997 ; 35 : 1427-1432
 
4) Koplan JP, et al. Value of stool cultures. Lancet 1980 ; 2 : 413-416
 
5) Choi SW, et al. To culture or not to culture : Fecal lactoferin screening for inflammatory bacterial diarrhea. J Clin Microbiol 1996 ; 34 : 928-932
 
6) Chitkara YK, et al. Development and implementation of cost-effective guidelines in the laboratory investigation of diarrhea in a community hospital. Arch Intern Med 1996 ; 156 : 1445-1448
 
P.171 掲載の参考文献
1) Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children : a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001 ; 33 (suppl 2) : S17-25
 
2) Van Niel CW, Feudtner C, Garrison MM, et al. Lactobacillus therapy for acute infectious diarrhea in children : a meta-analysis. Pediatrics 2002 ; 109 (4) : 678-684
 
3) Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004 ; (2) : CD003048
PubMed
4) McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007 ; 5 (2) : 97-105. Epub 2005
 
5) Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea : a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006 ; 6 (6) : 374-382
 
P.173 掲載の参考文献
1) Solomkin JS, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003 ; 37 : 997-1005
 
2) Cohn SM, Lipsett PA, Buchman TG, et al. Kowalsky SF Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000 ; 232 (2) : 254-262
 
3) Ohlin B, Cederberg A, Forssell H, et al. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999 ; 165 (9) : 875-884
 
4) Teppler H, McCarroll K, Gesser RM, et al. Surgical infections with enterococcus : outcome in patients treated with ertapenem versus piperacillin-tazobactam. Surg Infect (Larchmt) 2002 ; 3 (4) : 337-349
 
5) Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 2004 ; 23 (2) : 73-77
 
6) Sotto A. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002 ; 50 : 569-576
 
7) Patel R, Badley AD. Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation 1996 ; 61 : 1192-1197
 
8) Barrall DT, Kenney PR, Slotman GJ, et al. Enterococcal bacteremia in surgical patients. Arch Surg 1985 ; 120 : 57-63
 
9) Matthaiou DK, Peppas G, Bliziotis IA, et al. Ciprofloxacin/metronidazole versus beta-lactam-based treatment of intra-abdominal infections : a meta-analysis of comparative trials. Int J Antimicrob Agents 2006 ; 28 (3) : 159-165. Epub 2006 Aug 8.
 
P.176 掲載の参考文献
1) Muller EL, Pitt HA, Thompson JE Jr, et al. Antibiotics in infections of the biliary tract. Surg Gynecol Obstet 1987 ; 165 (4) : 285-292
 
2) Gerecht WB, Henry NK, Hoffman WW, et al. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med 1989 ; 149 (6) : 1279-1284
 
3) Thompson JE Jr, Pitt HA, Doty JE, et al. Broad spectrum penicillin as an adequate therapy for acute cholangitis. Surg Gynecol Obstet 1990 ; 171 (4) : 275-282
 
4) Chacon JP, Criscuolo PD, Kobata CM, et al. Prospective randomized comparison of pefloxacin and ampicillin plus gentamicin in the treatment of bacteriologically proven biliary tract infections. J Antimicrob Chemother 1990 ; 26 (suppl B) : 167-172
 
5) Thompson JE Jr, Bennion RS, Roettger R, et al. Cefepime for infections of the biliary tract. Surg Gynecol Obstet 1993 ; 177 (suppl) : 30-34, discussion 35-40
 
6) Sung JJ, Lyon DJ, Suen R, et al. Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis : a randomized, controlled clinical trial. J Antimicrob Chemother 1995 ; 35 (6) : 855-864
 
7) Karachalios GN, Nasiopoulou DD, Bourlinou PK, et al. Treatment of acute biliary tract infections with ofloxacin : a randomized, controlled clinical trial. Int J Clin Pharmacol Ther 1996 ; 34 (12) : 555-557
 
8) Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients : systematic review and meta-analysis of randomised trials. BMJ 2004 ; 328 (7441) : 668, Epub 2004 Mar 2. Review. Erratum in : BMJ 2004 ; 328 (7444) : 884
 
9) 急性胆道炎の診療ガイドライン作成出版委員会. 科学的根拠に基づく急性胆管炎・胆嚢炎の診療ガイドライン. 東京 : 医学図書出版, 2005
 
P.179 掲載の参考文献
1) Barie PS, Fischer E. Acute acalculous cholecystitis. J Am Coll Surg 1995 ; 180 : 232-244
 
2) 急性胆道炎の診療ガイドライン作成委員会. 急性胆管炎・胆嚢炎の診療ガイドライン. 第一版. 東京 : 医学図書出版, 2005
 
3) Law CHL, Tandan VR. Gallstone disease : surgical treatment. Evidence Based Gastroenterology and Hepatology. London : BMJ Books, 1999 : 260-270
 
4) Indar AA, Beckingham IJ. Acute cholecystitis. BMJ 2002 ; 325 : 639-643
 
5) Csendes A, Burdiles P, Maluenda F, et al. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg 1996 ; 131 : 389
PubMed
6) Ransohoff DF, Miller GL, Forsythe SB, et al. Outcome of acute cholecystitis in patients with diabetes mellitus. Ann Intern Med 1987 ; 106 : 829-832
 
7) Muller EL, Pitt HA, Thompson JE Jr, et al. Antibiotics in infections of the biliary tract. Surg Gynecol Obstet 1987 ; 165 : 285-292
 
8) Friedlender J, Meyer P, Marti MC, et al. Comparative study of ceftriaxone and cefoperazone in the treatment of acute cholecystitis. Chemotherapy 1988 ; 34 : 30-33
 
9) Chacon JP, Criscuolo PD, Kobata CM, et al. Prospective randomized comparison of pefloxacin and ampicillin plus gentamicin in the treatment of bacteriologically proven biliary tract infections. J Antimicrob Chemother 1990 ; 26 (suppl B) : 167-172
 
10) Thompson JE Jr, Bennion RS, Roettger R, et al. Cefepime for infections of the biliary tract. Surg Gynecol Obstet 1993 ; 177 (suppl) : 30-34
 
11) Yellin AE, Berne TV, Appleman MD, et al. A randomized study of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis. Surg Gynecol Obstet 1993 ; 177 (suppl) : 23-29
PubMed
12) Karachalios GN, Nasiopoulou DD, Bourlinou PK, et al. Treatment of acute biliary tract infections with ofloxacin : a randomized, controlled clinical trial. Int J Clin Pharmacol Ther 1996 ; 34 : 555-557
 
13) Shinagawa N, Takeda S, Oohira S, et al. Efficacy and safety of sulbactam/cefoperazone for hepato-biliary infections. Jpn J Antibiot 1997 ; 50 : 862-870
 
P.182 掲載の参考文献
1) Joseph S, Solomkin, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdminal infections. Clinical Infectious Diseases 2003 ; 37 : 997
PubMed
2) Lennard ES, Dellinger EP, et al. Implications of leuukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg 1982 ; 195 : 19-24
 
3) Stone HH, Bourneuf AA, et al. Reliability of criteria for predicting persistent or recurrent sepsis. Arch Surg 1985 ; 120 : 17-20
PubMed
4) Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery : a prospective study. Br J Surg 1994 ; 81 (7) : 989-991
 
5) Gleisner AL, Argenta R, Pimentel M, et al. Infective complications according to duration of antibiotic treatment in acute abdomen. Int J Infect Dis 2004 ; 8 (3) : 155-162
 
P.185 掲載の参考文献
1) Solomkin JS, Mazusuki JE, Baron EJ, et al. Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections. Clin Infect Dis 2003 ; 37 : 997-1005
 
2) Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005 ; 104 (1) : 205-212
 
3) Bartlett JG. Anaerobic bacterial infections. UpToDate (15.1), www.uptodate.com
 
P.188 掲載の参考文献
1) Scoular A, et al. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transmit Infect 2002 ; 78 : 21-25
 
2) Wald A, et al. Polymerase Chain Reaction for Detection of Herpes Simplex Virus (HSV) DNA on Mucosal Surfaces : Comparison with HSV Isolation in Cell Culture. JID 2003 ; 188 : 1345-1351
 
3) Ramaswamy M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transmit Infect 2004 ; 80 : 406-410
 
4) Whittington WL, et al. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transmit Dis 2001 ; 28 : 99-104
 
5) Morrow RA, Friedrich D. Inaccuracy of certain commercial enzyme immunoassays in diagnosing genital infections with herpes simplex virus type 1 (HSV-1) and HSV-2. Am J Clin Pathol 2003 ; 120 : 839-844
 
6) Sexually Transmitted Diseases Treatment Guideline 2006 ; Genital HSV Infections. MMWR Recomm Rep 2006 ; 55 (RR-11) : 16-20
 
7) 菅生元康. 性器ヘルペス. 日本臨牀 2006 ; 64 : 252-255
 
P.192 掲載の参考文献
1) Katchman EA, et al. Three-day vs longer duration of antibiotic treatment for cystitis in women : systematic review and meta-analysis. Am J Med 2005 ; 118 : 1196-1207
 
2) Lutters M, et al ; Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women (Cochrane Review). In : The Cochrane Library 2006 Issue 2
 
3) Hooton TM, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women. A randomized trial. JAMA 2005 ; 293 : 949-955
 
4) Kavatha D, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrobial Agents and Chemotherapy 2003 ; 47 (3) : 897-900
 
5) McCarty J, et al ; A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med 1999 ; 106 (3) : 292-299
 
6) Jepson RG, et al. Cranberries for preventing urinary tract infections (Cochrane Review). In : The Cochrane Library 2006 Issue 2
 
7) Hooton TM, et al. Acute cystitis in women, UpToDate (R) 15.1 2007
 
8) Hooton TM, et al. Recurrent urinary tract infection in women, UpToDate (R) 15.1 2007
 
P.195 掲載の参考文献
1) Warren JW, Abrutyn E, Hebel JR, et al. IDSA practice guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clinical Infectious Diseases 1999 ; 29 : 745-758
 
2) Hooton TM, Winter C, Tiu F, et al. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995 ; 273 (1) : 41-45
 
3) Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women : a randomized trial. JAMA 2005 ; 293 (8) : 949-955
 
4) Kavatha D, Giamarellou H, Alexiou Z, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother 2003 ; 47 (3) : 897-900
 
5) Bailey RR. Single dose therapy of urinary tract infection. Sydney, Australia : ADIS Health Science Press, 1983, 1
 
6) Norrby SR. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis 1990 ; 12 (3) : 458-467
 
7) Leibovici L, Wysenbeek AJ. Single-dose antibiotic treatment for symptomatic urinary tract infections in women : a meta-analysis of randomized trials. Q J Med 1991 ; 78 (285) : 43-57
 
8) Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999 ; 281 (8) : 736-738
 
9) Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997 ; 11 (3) : 551-581
 
10) Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol 1993 ; 149 (5) : 1046-1048
 
11) Johnson JR, Lyons MF 2nd, Pearce W, et al. Therapy for women hospitalized with acute pyelonephritis : a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days. J Infect Dis 1991 ; 163 (2) : 325-330
 
12) Stamm WE, McKevitt M, Counts GW. Acute renal infection in women : treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med 1987 ; 106 (3) : 341-345
 
13) Ode B, Broms M, Walder M, et al. Failure of excessive doses of ampicillin to prevent bacterial relapse in the treatment of acute pyelonephritis. Acta Med Scand 1980 ; 207 (4) : 305-307
 
14) Jernelius H, Zbornik J, Bauer CA. One or three weeks' treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam. Acta Med Scand 1988 ; 223 (5) : 469-477
PubMed
15) Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999 ; 29 (4) : 745-758
 
16) Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections : a prospective randomized clinical trial. Arch Intern Med 1999 ; 159 (1) : 53-58
 
17) Czaja CA, Scholes D, Hooton TM, et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007 ; 45 (3) : 273-280. Epub 2007 Jun 19
 
P.200 掲載の参考文献
1) Albert X, Huertas I Pereiro IS et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women (Review). Cochrane Database Syst Rev 2004 ; Issue 3
PubMed
2) Melekos MD, Asbach HW, Melekos GE. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997 ; 157 (3) : 935-939
 
3) Hooton TM, Stamm WE. Recurrent urinary tract infection in women. UpToDate(R) 14.3 2006
 
4) Falagas ME, Betsi GI, Tokas T, et al. Probiotics for prevention of recurrent urinary tract infection in women. Drugs 2006 ; 66 (9) : 1253-1261
 
5) Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2004 ; Issue 2
 
6) Kontiokari T, Sundqvist K, Nuutinen M, et al. Randomised trial of cranberry-lingoberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001 ; 322 : 1571-1575
 
7) Rozenberg S, Pastijn A, Gevers R, et al. Estrogen Therapy in older patients with recurrent urinary tract infections : A review. Int J Fertil 2004 ; 49 (2) : 71-74
 
8) Smaill F. Antibiotics for asymptomatic bacteriuria in pregnancy (Review). Cochrane Database Syst Rev 2001 ; Issue 2
 
9) Villar J, Widmer M, Lydon-Rochelle MT, et al. Duration of treatment for asymptomatic bacteriuria during pregnancy (Review). Cochrane Database Syst Rev 2000 ; Issue 2
 
10) Vazquez JC, Villar J. Treatments for symptomatic urinary tract infections during pregnancy (Review). Cochrane Database Syst Rev 2003 ; Issue 4
 
11) Williams GJ, Wie L, Lee A, et al. Long-term antibiotics for preventing recurrent urinary tract infection in children (Review). Cochrane Database Syst Rev 2006 ; Issue 3
 
12) Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys : a systematic review of randomized trials and observational studies. Arch Dis Child 2005 ; 90 : 853-858
 
13) McNaughton Collins M, Mac Donald R, Wilt T. Intervention for chronic abacterial prostatitis (Review). Cochrane Database Syst Rev 1999 ; Issue 4
 
14) McNaughton Collins M, Wilt T. Allopurinol for chronic prostatitis (Review). Cochrane Database Syst Rev 2002 ; Issue 4
 
15) Niel-Weise BS, van den Broek PJ. Urinary catheter policies for long-term bladder drainage (Review). Cochrane Database Syst Rev 2005 ; Issue 1
 
16) Schooff M, Hill K. Antibiotics for recurrent urinary tract infections. American Family Physician 2005 ; 71 (7) : 1301-1302
 
P.203 掲載の参考文献
1) WHO website : Available at : http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html Accessed Apr 27, 2007
 
2) 井岡亜希子, 他. 産婦人科の実際 2006 ; 55 (10) : 1479-1483
 
3) 今野良, 他. 産科と婦人科 2006 ; 73 (9) : 1079-1089
 
4) CDC website. HPV vaccine. Available at : http://www.cdc.gov/nip/vaccine/hpv/hpv-faqs.htm Accessed Apr 27, 2007
 
5) Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia : a randomized controlled trial. Obstet Gynecol 2006 ; 107 : 18-27
 
6) Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002 ; 347 : 1645-1651
 
7) Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women : a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 ; 6 : 271-278
 
8) Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006 ; 24 : 5571-5583
 
9) Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 ; 95 : 1459-1466
 
10) Sattler C. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). [Abstract LB2-25] In : 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005. (American Society for Microbiology, Washington, DC, 2005)
 
11) Markowitz LE, Dunne EF, Saraiya M, et al. Centers for Disease Control and Prevention ; Advisory Committee on Immunization Practice. Quadrivalent Human Papillomavirus Vaccine : Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 ; 56 (RR-2) : 1-24 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm
 
12) FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 ; 356 : 1915-1927
 
13) Harper DM, Franco E, Wheeler CM, et al. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 : follow-up from a randomize control trial. Lancet 2006 ; 367 : 1247-1255
 
14) 中山裕樹. 子宮頸癌検診の現状と課題. 産婦人科の実際 2006 ; 55 (10) : 1485-1489
 
P.207 掲載の参考文献
1) Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004 ; 39 : 885
PubMed
2) Lipsky BA, Pecoraro RE, Larson SA, et al. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990 ; 150 : 790
PubMed
3) Joseph WS, Axler DA. Microbiology and antimicrobial therapy of diabetic foot infections. Clin Podiatr Med Surg 1990 ; 7 : 467
PubMed
4) Urbancic-Rovan V, Gubina M. Bacteria in superficial diabetic foot ulcers. Diabet Med 2000 ; 17 : 814
PubMed
5) Sims D, Keating SE, DeVincentis AF. Bacteriology of diabetic foot ulcers. J Foot Surg 1984 ; 23 : 149
PubMed
6) Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections : bacteriologic analysis. Arch Intern Med 1986 ; 146 : 1935
PubMed
7) Bamberger DM, Duas GP, Gerding DN. Osteomyelitis in the feet of diabetic patients. Am J Med 1987 ; 83 : 653
 
8) Lavary LA, Sariaya M, Ashry H, et al. Microbiology of osteomyelitis in diabetic patients. J Foot Ankle Surg 1995 ; 34 : 61
 
9) Tan JS, Friedman NM, Hazelton-Miller C, et al. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 1996 ; 23 : 286
PubMed
10) Newman LG, Walter J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers : diagnosing and monitoring by leukocyte scanning with indium In111 oxyquinolone. JAMA 1991 ; 266 : 1246
 
11) Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997 ; 25 : 1318
PubMed
P.210 掲載の参考文献
1) Lazzarini L, Lipsky BA, et al. Antibiotic treatment of osteomyelitis : what have we learned from 30 years of clinical trials? Intl J Infect Dis 2005 ; 9 : 127-138
 
2) Saux NL, Howard A, et al. Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis ; a systematic review. BMC Infect Dis 2002 ; 2 : 16
 
3) Lipsky BA, Anthony R. Berendt Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev 2000 ; 16 (suppl 1) : 42-46
 
P.212 掲載の参考文献
1) Chartier C, Grosshans E. Erysipelas : An update. Int J Dermatol 1996 ; 35 : 779
PubMed
2) Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005 ; 41 : 1373-1406
 
3) Baddour LM. Erysipelas. UpToDate(R) 14.3 2006 last changed on January 03, 2006
 
4) Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults : a comparative study. Br J Dermatol 1992 ; 127 : 155-159
 
5) Kobayashi I, Hasegawa M, Kanayama A, et al. Alarming trend of clarithromycin-resistant Streptococcus pyogenes in Japan (1998-2002). J Infect Chemother 2005 ; 11 (2) : 56-58
 
6) Bernard P, Bedane C, Mounier M, et al. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989 ; 125 : 779
PubMed
7) Goldgeir MH. The microbial evaluation of acute cellulitis. Cutis 1983 ; 31 : 649-655
 
8) Hook EW, Hooton TM, Horton CA, et al. : Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986 ; 146 : 295-297
 
9) Hugo-Persson M, Norlin K. Erysipelas and group G streptococci. Infection 1987 ; 15 : 184-187
 
10) Eriksson B, Jorup-Ronstrom C, Karkkonen K, et al. Erysipelas : Clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996 ; 23 : 1091
 
11) Krasagakis K, Samonis G, Maniatakis P, et al. Bullous erysipelas : clinical presentation, staphylococcal involvement and methicillin resistance. Dermatology 2006 ; 212 (1) : 31-35
 
P.217 掲載の参考文献
1) Zinner SH. New and unusual infections in neutropenic patients. Cancer Treat Res 1995 ; 79 : 173-184
 
2) Mathur P, Chaudhry R, Kumar L, et al. A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special reference to anaerobes. Med Oncol 2002 ; 19 : 267-272
 
3) Vidal AM, Sarria JC, Kimbrough RC, et al. Anaerobic bacteremia in a neutropenic patient with oral mucositis. Am J Med Sci 2000 ; 319 : 189-190
 
4) Reig M, Baquero F, Garcia-Campello M, et al. Leptotrichia buccalis bacteremia in neutropenic children. J Clin Microbiol 1985 ; 22 : 320-321
 
5) Weinberger M, Wu T, Rubin M, et al. Leptotrichia buccalis bacteremia in patients with cancer : report of four cases and review. Rev Infect Dis 1991 ; 13 : 201-206
 
6) Patel JB, Clarridge J, Schuster MS, et al. Bacteremia caused by a novel isolate resembling Leptotrichia species in a neutropenic patient. J Clin Microbiol 1999 ; 37 : 2064-2067
 
7) Candoni A, Fili C, Trevisan R, et al. Fusobacterium nucleatum : a rare cause of bacteremia in neutropenic patients with leukemia and lymphoma. Clin Microbiol Infect 2003 ; 9 : 1112-1115
 
8) Landsaat PM, van der Lelie H, Bongaerts G, et al. Fusobacterium nucleatum, a new invasive pathogen in neutropenic patients? Scand J Infect Dis 1995 ; 27 : 83-84
 
9) Fanourgiakis P, Vekemans M, Georgala A, at al. Febrile neutropenia and Fusobacterium bacteremia : clinical experience with 13 cases. Support Care Cancer 2003 ; 11 : 332-335
 
10) Coullioud D, Van der Auwera P, Viot M, et al. Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. Support Care Cancer 1993 ; 1 : 34-46
 
11) Chen CY, Tang JL, Hsueh PR, et al. Trend and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. J Formos Med Assoc 2004 ; 103 : 526-532
 
12) Karim M, Khan W, Farooqi B, et al. Bacterial isolates in neutropenic febrile patients. J Pak Med Assoc 1991 ; 41 : 35-37
 
13) Lark RL, McNeil SA, VanderHyde K, et al. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001 ; 33 : 338-343
 
14) Glenn J, Cotton D, Wesley R, et al. Anorectal infections in patients with malignant diseases. Rev Infect Dis 1988 ; 10 : 42-52
 
15) Fredricks DN, Schubert MM, Myerson D. Molecular identification of an invasive gingival bacterial community. Clin Infect Dis 2005 ; 41 : e1-4
 
16) Vogel C, Spadafora P, Horowitz B, et al. Myonecrosis due to Clostridium septicum in a patient with unexplained neutropenia : successful treatment with granulocyte colony-stimulating factor. South Med J 1995 ; 88 : 765-768
 
17) Barnes C, Gerstle JT, Freedman MH, et al. Clostridium septicum myonecrosis in congenital neutropenia. Pediatrics 2004 ; 114 : e757-760
 
18) Bar-Joseph G, Halberthal M, Sweed Y, et al. Clostridium septicum infection in children with cyclic neutropenia. J Pediatr 1997 ; 131 : 317-319
 
19) 著者不詳. Clostridium septicum and neutropenic enterocolitis. Lancet 1987 ; 2 : 608
 
20) Harrison's Principle of Internal Medicine, 16th ed. 2005 : 942
 
21) Harrison's Principle of Internal Medicine, 16th ed. 2005 : 940
 
22) Bartlett JG. "Anaerobic bacterial infections" www.uptodate.com (2008年1月27日に検索)
 
P.220 掲載の参考文献
1) Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 ; 34 (6) : 730-751
 
2) Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients : a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005 ; 5 (7) : 431-439
 
3) Paul M, Borok S, Fraser A, et al. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005 ; (3) : CD003914
PubMed
4) Viscoli C, Moroni C, Boni L, et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991 ; 13 (3) : 397-404
 
5) de Pauw B, Williams K, de Neeff J, et al. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1985 ; 28 (6) : 824-828
 
6) Menichetti F, Del Favero A, Guerciolini R, et al. Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulphamethoxazole. Infection 1986 ; 14 (6) : 261-267
PubMed
7) Verhagen CS, de Pauw B, de Witte T, et al. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1987 ; 31 (2) : 191-196
 
8) Erjavec Z, de Vries-Hospers HG, Laseur M, et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000 ; 45 (6) : 843-849
 
9) Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003 ; 37 (3) : 382-389
 
10) Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime : a randomized prospective study. Antimicrob Agents Chemother 1992 ; 36 (5) : 1062-1067
PubMed
11) Novakova I, Donnelly JP, De Pauw B. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 1991 ; 35 (4) : 672-678
 
12) Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006 ; 42 (5) : 597-607
 
13) Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia : systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005 ; 55 (4) : 436-444
 
14) Robbins GK. Fever in the neutropenic adult patient with cancer. In : UpToDate 15.1 Rose, BD (ed), UpToDate, Waltham, MA ; 2007
 
P.224 掲載の参考文献
1) Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia : systematic review and meta-analysis. BMJ 2003 ; 326 : 1111-1120
 
2) Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients : systematic review and meta-analysis of randomised trials. BMJ 2004 ; 328 : 668-682
 
3) Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis : a meta-analysis of comparative trials. J Antimicrob Chemother 2006 ; 57 : 639-647
 
4) Robbins CK. Fever in the neutropenic adult patient with cancer. Up to date 15.2 2007 (Cited 2007 May. 20)
 
5) Baddour LM, et al. Infective Endocarditis : Diagnosis, Antimicrobial Therapy, and Management of Association : A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association : Endorsed by the Infectious Diseases Society of America. Circulation 2005 ; 111 : 394-343
 
6) Drew RH. Aminoglycoside. Up to date 15.2 2007 (Cited 2007 May. 25)
 
P.227 掲載の参考文献
1) Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2005 ; CD004386
PubMed
2) Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis : antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005 ; 142 : 979-995
 
3) van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients : a systematic review of randomised controlled trials. Eur J Cancer 2005 ; 41 : 1372-1382
 
4) Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients : a meta-analysis. J Clin Oncol 1998 ; 16 : 1179-1187
 
5) Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients : a meta-analysis. Clin Infect Dis 1996 ; 23 : 795-805
 
6) Gafter-Gvili A, Paul M, Fraser A, et al. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance : systematic review and meta-analysis. J Antimicrob Chemother 2007 ; 59 : 5-22
 
7) Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005 ; 353 : 977-987
 
8) Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005 ; 353 : 988-998
 
P.230 掲載の参考文献
1) Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor : effects on normal and leukemic myeloid cells. Science 1986 ; 232 : 61-65
 
2) Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990 ; 65 : 2185-2195
 
3) Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients : A systematic review of the literature with meta-analysis. Support Care Cancer 2002 ; 10 : 181-188
 
4) Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia : A meta-analysis of randomized controlled trials. J Clin Oncol 2005 ; 23 : 4198-4214
 
5) Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia : A multi-center randomized trial. J Natl Cancer Inst 2001 ; 93 : 31-38
 
6) Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendation for the use of white blood cell growth factors : An evidence-based clinical practice guideline. J Clin Oncol 2006 ; 24 : 3187-3205
 
7) Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000 ; 18 : 3038-3051
 
8) Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia : A prospective, two-center validation of a prediction rule. J Clin Oncol 1992 ; 10 : 316-322
 
9) Kuderer NM, Crawford J, Dale DC, et al. Complications and costs associated with febrile neutropenia in hospitalized adult cancer patients. J Clin Oncol 2004 ; 22 (abstr 6049)
 
10) Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006 ; 42 : 2433-2453
 
11) Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clin Infect Dis 2002 ; 34 : 730-751
 
P.233 掲載の参考文献
1) Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 ; 34 : 730-751
 
2) Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997 ; 25 : 551-573
 
3) Cotton D, Gress J, et al. Pathogen-specific vs. broad-spectrum antibiotics for granulocytopenic cancer patients with proven infection. Program and abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 8-10, 1984. Washington, D.C. : American Society for Microbiology, 1984 : 158. abstract, 1984
 
4) Pizzo PA, Ladisch S, Ribichaud K. Treatment of gram-positive septicemia in cancer patients. Cancer 1980 ; 45 : 206-207
 
5) Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979 ; 67 : 194-200
 

4章 微生物別 感染症診療にかかわるエビデンス

P.236 掲載の参考文献
1) Karchmer AW et al. Staphylococcus epidermidis causing prosthetic valve endocarditis : microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983 ; 98 (4) : 447-455
 
2) Mandell GL, Moorman DR, et al. Treatment of experimental staphylococcal infections : effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob Agents Chemother 1980 ; 17 : 658-662
 
3) Van der Auwera P, et al. Double-blind, placebo--control study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985 ; 28 : 467-472
 
4) Van der Auwera P, et al. Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis 1983 ; 5 (suppl 3) : S515-522
 
5) Norden CW, et al. Chronic osteomyelitis caused by Staphylococcus aureus : controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986 ; 79 : 947-951
 
6) Darouiche RO, et al. Antibiotic penetration of and bacterial activity within endothelial cells. Antimicrob Agents Chemother 1994 ; 38 : 1059-1064
 
7) Levine DP, et al. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991 ; 115 : 674-680
PubMed
8) Shelburne SA, et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combination. Antimicrob Agents Chemother 2004 ; 48 : 4016-4019
 
P.238 掲載の参考文献
1) Shorr AF, Kunkel MJ, Kollef MJ. Linezolid versus vancomycin for Staphylococcus aureus bacteremia : pooled analysis of randomized studies. Antimicrob Chemother 2005 ; 56 : 923-929
 
2) Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia : a randomized, double-blind, multicenter study. Clin Infect Dis 2001 ; 32 : 402-412
 
3) Wunderink RG, Cammarata S, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003 ; 25 : 980-991
 
4) http://www.fda.gov/cder/drug/InfoSheets/HCP/linezolidHCP.htm
 
5) Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospevtive randomized comparison of quinupristin-dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000 ; 161 : 753-762
 
6) Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005 ; 40 : 374-380
 
7) Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006 ; 355 : 653-665
 
8) Cepada JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill : a randomized, double-blind, multicenter study. J Antimicrob Chemother 2004 ; 53 : 344-355
 
9) Rolston KV, Nguyen H, Amos G, et al. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of Gram-positive bacteremia in patients with cancer. J Infect Dis 1994 ; 169 : 350-355
 
10) Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infection in immunocompromized hosts. Antimicrob Agents Chemother 1991 ; 35 : 451-457
 
11) Smith SR, Cheesbrough J, Speraring R, et al. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 1989 ; 33 : 1193-1197
 
12) Wunderrink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003 ; 124 : 1789-1797
 
13) Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia : retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004 ; 30 : 388-394
 
P.241 掲載の参考文献
1) CDC. Community-acquired methicillin-resistant Staphylococcus aureus infections-Michigan. MMWR 1981 ; 30 : 185-187
 
2) CDC. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR 1999 ; 48 : 707-710
 
3) Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003 ; 290 : 2976-2984
 
4) Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. NEJM 2006 ; 355 : 666-674
 
5) Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci : should clinicians and microbiologists be concerned? Clin Infect Dis 2005 ; 40 : 280-285
 
6) Moreillon P, Que YA, Glauser MP. Staphylococcus aureus (including Staphylococcal toxic shock). In : Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed., Philadelphia : Churchill Livingstone, 2004 : 2321-2351
 
7) Swartz MN, Pasternack MS. Cellulitis and subcutaneous tissue infections. In : Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed., Philadelphia : Churchill Livingstone, 2004 : 1172-1194
 
8) Llera JL, Levy RC. Treatment of cutaneous abscess : a double-blind clinical study. Ann Emerg Med 1985 ; 14 : 15-19
 
9) Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin- resistant and-susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007 ; 44 : 483-492
 
10) Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. NEJM 2005 ; 352 : 1436-1444
 
11) Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004 ; 23 : 123-127
 
12) Ruhe JJ, Smith N, Bradsher RW, et al. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections : Impact of antimicrobial therapy on outcome. Clin Infect Dis 2007 ; 44 : 777-784
 
13) Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community : Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html
 
P.246 掲載の参考文献
1) Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis : a phase III randomised double-blind trial. Lancet 2007 ; 369 (9572) : 1519-1527
 
2) Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005 ; 49 (4) : 1331-1336
PubMed
3) de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004 ; 39 (6) : 842-849
 
4) Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin : a novel systemic antifungal agent. Aliment Pharmacol Ther 2004 ; 20 (4) : 475-481
 
5) van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 ; 39 (10) : 1407-1416
 
6) de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005 ; 21 (7) : 899-907
 
7) Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006 ; 355 (11) : 1154-1159
 
8) Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005 ; 24 (10) : 654-661
 
9) Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004 ; 36 (5) : 372-379
 
10) Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin : reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004 ; 48 (9) : 3407-3411
 
11) Clemons KV, Espiritu M, Parmar R, et al. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006 ; 50 (4) : 1293-1297
 
P.248 掲載の参考文献
1) Rex JH, Pappas PG, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placeboversus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003 ; 36 (10) : 1221-1228
 
2) Mora-Duarte J, Betts R, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 ; 347 (25) : 2020-2029
 
3) Mattiuzzi GN, Alvarado G, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006 ; 50 (1) : 143-147
 
4) Ostrosky-Zeichner L, D. Kotoyiannis, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005 ; 24 (10) : 654-661
 
5) Kevin W Garey, Milind Rege, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia : a multi-institutional study. Clin Infect Dis 2006 ; 43 (1) : 25-31
 
6) Breit SM, Hariprasad SM, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005 ; 139 (1) : 135-140
 
7) DiNubile MJ, Hille D, et al. Invasive candidiasis in cancer patients : observations from a randomized clinical trial. J Infect 2005 ; 50 (5) : 443-449
 
8) Kuse ER, Chetchotisakd P, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis : a phase III randomised double-blind trial. Lancet 2007 ; 369 (9572) : 1519-1527
 
9) Pappas PG, Rotstein CM, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007 ; 45 (7) : 883-893. Epub 2007 Aug 29
 
P.252 掲載の参考文献
1) Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 ; 347 : 408-415
 
2) Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002 ; 35 : 359-366
 
3) Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998 ; 27 : 1406-1412
 
4) Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003 ; 109 : 111-118
 
5) Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001 ; 33 : e83-90
PubMed
6) Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 ; 39 : 1563-1571
PubMed
P.255 掲載の参考文献
1) Sugino Y, Fujii M, Kato M, et al. Micafungin therapy for a case of chronic necrotizing pulmonary aspergillosis. Nihon Kokyuki Gakkai Zasshi 2006 ; 44 : 458-463
 
2) Gefter WB, Weingrad TR, Epstein DM, et al."Semi-invasive" pulmonary aspergillosis : a new look at the spectrum of aspergillus infections of the lung. Radiology 1981 ; 140 : 313-321
 
3) Binder RE, Faling LJ, Pugatch RD, et al. Chronic necrotizing pulmonary aspergillosis : a discrete clinical entity. Medicine (Baltimore) 1982 ; 61 : 109-124
 
4) Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001 ; 7 (suppl 2) : 25-31
 
5) 深在性真菌症のガイドライン作成委員会編. 深在性真菌症の診断・治療ガイドライン, 2007
 
6) Saraceno JL, Phelps DT, Ferro TJ, et al. Chronic necrotizing pulmonary aspergillosis : approach to management. Chest 1997 ; 112 : 541-548
 
7) Schiraldi GF, Gramegna G, De Rosa C, et al. Chronic pulmonary aspergillosis : current classification and therapy. Curr Opin Investig Drugs 2003 ; 4 (2) : 186-191
 
8) Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002 ; 121 (6) : 1988-1999
 
9) Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000 ; 30 : 696-709
 
10) Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in non-immunocompromised patients. Chest 2007 ; 131 : 1435-1441
 
11) Sugino Y, Fujii M, Kato M, et al. Micafungin therapy for a case of chronic necrotizing pulmonary aspergillosis. Nihon Kokyuki Gakkai Zasshi 2006 ; 44 (6) : 458-463
 
12) Furugen M, Haranaga S, Touyama M, et al. Two cases of pulmonary aspergillosis successfully treated with combinated micafungin and itraconazole therapy. Kansenshogaku Zasshi 2005 ; 79 (12) : 951-956
 
P.257 掲載の参考文献
1) Hornbuckle K, Chak A, Lazarus HM, et al. Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998 ; 9 (3) : 307-311
 
2) Cooper GS, Lederman MM, Salata RA. A predictive model to identify Clostridium difficile toxin in hospitalized patients with diarrhea. Am J Gastroenterol 1996 ; 91 (1) : 80-84
 
3) American College of Gastroenterology and Practice Parameters Committee, Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997 ; 92 (5) : 739-750
 
4) Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician 2005 ; 71 (5) : 921-928. Review
PubMed
5) Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004 ; 171 (1) : 51-58
 
6) Simor AE, Bradley SF, Strausbaugh LJ, et al. SHEA Long-Term-Care Committee. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002 ; 23 (11) : 696-703
 
7) Roth AR, Basello GM. Approach to the adult patient with fever of unknown origin. Am Fam Physician 2003 ; 68 (11) : 2223-2228
 
8) Vargas SO, Horensky D, Onderdonk AB. Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A. J Clin Pathol 1997 ; 50 (12) : 996-1000
 
9) De Girolami PC, Hanff PA, Eichelberger K, et al. Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A. J Clin Microbiol 1992 ; 30 (5) : 1085-1088
 
10) Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis : should CT guide therapy? AJR Am J Roentgenol 2001 ; 176 (3) : 635-639
 
11) Boland GW, Lee MJ, Cats AM, et al. Antibiotic-induced diarrhea : specificity of abdominal CT for the diagnosis of Clostridium difficile disease. Radiology 1994 ; 191 (1) : 103-106
 
12) Alonso R, Munoz C, Gros S, et al. Rapid detection of toxigenic Clostridium difficile from stool samples by a nested PCR of toxin B gene. J Hosp Infect 1999 ; 41 (2) : 145-149
 
13) Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea : a systematic review. J Antimicrob Chemother 2003 ; 51 : 1339-1350
 
14) Bignardi GE. Related articles, links risk factors for Clostridium difficile infection. J Hosp Infect 1998 ; 40 (1) : 1-15
 
15) Peled N, Pitlik S, Samra Z, et al. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol 2007 ; 28 (4) : 377-381. Epub 2007
 
16) Katz DA, Bates DW, Rittenberg E, et al. Predicting Clostridium difficile stool cytotoxin results in hospitalized patients with diarrhea. J Gen Intern Med 1997 ; 12 (1) : 57-62
 
17) Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996 ; 100 (5) : 487-495
 
P.260 掲載の参考文献
1) Bricker E, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005 ; 1 : CD004610. Review.
PubMed
2) Zimmerman MJ, et al. Review article : treatment of Clostridium difficile infection. Aliment Pharmacol Ther 1997 ; 11 (6) : 1003-1012
 
3) Wenisch C, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996 ; 22 (5) : 813-818. Erratum in : Clin Infect Dis 1996 ; 23 (2) : 423
 
4) Teasley DG, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983 ; 2 (8358) : 1043-1046
 
P.263 掲載の参考文献
1) Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea : a systematic review. CMAJ 2005 ; 173 : 167-170
 
2) McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006 ; 101 : 812-822
 
3) Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study : effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004 ; 7 : 59-62
 
4) McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994 ; 271 : 1913-1918
 
5) Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease : use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000 ; 31 : 1012-1017
 
6) Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea : a double-blind, placebo-controlled trial. Scand J Infect Dis 2003 ; 35 : 365-367
 
7) Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii : a prospective study. Gastroenterology 1989 ; 96 : 981-988
 
8) McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995 ; 90 : 439-448
 
9) Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998 ; 36 : 171-174
 
10) Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea : a randomized, placebo-controlled trial. Mayo Clin Proc 2001 ; 76 : 883-889
 
11) Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000 ; 95 : S11-13
 
12) Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005 ; 54 : 905-906
 
13) Sartor RB. Probiotics for gastrointestinal disease. UpToDate 15.1. January 2, 2007
 
P.266 掲載の参考文献
1) Pepin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile - associated disease in Quebec, Canada. Clin Infect Dis 2006 ; 42 (6) : 758-764. Epub 2006
 
2) McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle : treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002 ; 97 (7) : 1769-1775
 
3) Mogg GA, Arabi Y, Youngs D, et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl 1980 ; (suppl 22) : 41-45
 
4) Kreutzer EW, Milligan FD. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J 1978 ; 143 (3) : 67-72
 
5) Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1982 ; 77 (4) : 220-221
 
6) Aboudola S, Kotloff KL. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003 ; 71 (3) : 1608-1610
 
7) Kotloff KL, Wasserman SS. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001 ; 69 (2) : 988-995
 
P.269 掲載の参考文献
1) Shetler K, Nieuwenhuis R, Wren SM, et al. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc 2001 ; 15 (7) : 653-659
 
2) Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis : case series and review of the literature. Clin Infect Dis 2002 ; 35 (6) : 690-696
 
3) Nomura K, Fukumoto K, Shimizu D, et al. Pseudomembranous colitis presenting as acute colonic obstruction without diarrhea in a patient with gastric Burkitt lymphoma. World J Gastroenterol 2005 ; 11 (17) : 2681-2683
 
4) 青木眞. 抗菌薬の使用に伴う腸炎 (偽膜性腸炎, Clostridium difficile腸炎, Clostridium difficile関連下痢症). In : 青木眞. レジデントのための感染症診療マニュアル 第2版. 東京 : 医学書院, 2008 ; 690-699
 
5) Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997 ; 41 (3) : 366-370
 
6) Beales IL. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 2002 ; 51 (3) : 456
PubMed
7) Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004 ; 53 (5) : 882-884
 
8) McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006 ; 49 (5) : 640-645
 
9) 岩田健太郎. 偽膜性大腸炎の治療. In : 岩田健太郎, 宮入烈著. 抗菌薬の考え方, 使い方, ver. 2. 東京 : 中外医学社, 2006 ; 164-167
 
10) Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001 ; 44 (8) : 1176-1180
 
11) Liacouras CA, Piccoli DA. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol 1996 ; 22 (3) : 186-189
 
12) Schwan A, Sjolin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984 ; 16 (2) : 211-215
 
P.273 掲載の参考文献
1) National Clostridium difficile Standards Group. Report to the Department of Health. J Hosp Infect 2004 ; 56 S1 : 1-38
 
2) Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997 ; 92 : 739-50
 
3) Guideline for Environmental Infection Control in Health-Care Facilities, 2003 ; 84-85 http://www.cdc.gov/ncidod/dhqp/gl_environinfection.html
 
4) McFarland LV, et al. Nosocomial acquisition of Clostridium difficile infection. New Engl J Med 1989 ; 320 : 204-210
 
5) Johnson S, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990 ; 88 : 137-140
 
6) Jernigan JA, et al. A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect Control Hosp Epidemiol 1998 ; 19 : 494-499
 
7) Worsley MA. Infection control and prevention of Clostridium difficile infection. J of Antimicro Chemo 1998 ; 41s : 59-66
 
8) Kaatz GW, et al. Acquisition of Clostridium difficile from the hospital environment. Am J of Epidemiol 1988 : 127 ; 1289-1293
 
9) Mayfield JL, et al. Environmental control to reduce transmission of Clostridium difficile. Clin Inf Dis 2000 ; 31 : 995-1000
 
P.276 掲載の参考文献
1) Yamamoto S. IDWR感染症の話結核 http://idsc.nih.go.jp/idwr/kansen/k03/k03-07/k03_07.html
 
2) (財) 結核予防会ホームページ http://www.jata.or.jp/
 
3) Rodrigues LC, et al. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis : a meta-analysis. Int J Epidemiol 1993 ; 22 (6) : 1154-1158
 
4) Colditz GA, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994 ; 271 (9) : 698-702
 
5) Black GF, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK : two randomised controlled studies. Lancet 2002 ; 359 (9315) : 1393-1401
 
6) Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996 ; 348 (9019) : 17-24
PubMed
7) Rodrigues LC, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil : the BCG-REVAC cluster-randomised trial. Lancet 2005 ; 366 (9493) : 1290-1295. Epub 2005
 
8) Soysal A, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact : a prospective community-based study. Lancet 2005 ; 366 (9495) : 1443-1451
 
9) Aronson NE, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives : A 60-year follow-up study. JAMA 2004 ; 291 (17) : 2086-2091
 
10) Bass JB. BCG vaccination. UpToDate 15. 2 April 20, 2006
 
11) WHO position paper on BCG (January 2004) http://www.who.int/immunization/wer7904BCG_Jan04_position_paper.pdf
 
P.279 掲載の参考文献
1) Menzies D, Pai M, Comstock G. Meta-analysis : new tests for the diagnosis of latent tuberculosis infection : areas of uncertainty and recommendations for research. Ann Intern Med 2007 ; 146 (5) : 340-354
 
2) 青木正和. 結核感染の診断 3. ツベルクリン反応の判定 2. わが国での判定法. In : 青木正和. 医師・看護職のための結核病学 2 感染・発症の診断. 平成16年度改訂版. 東京 : 財団法人結核予防会, 2004 ; 8-10
 
3) Toivgoogiin A, Toyota M, Yasuda N, et al. Validity of using tuberculin skin test erythema measurement for contact investigation during a tuberculosis outbreak in schoolchildren previously vaccinated with BCG. J Epidemiol 2005 ; 15 (2) : 56-64
 
4) Kimura M, Comstock GW, Mori T. Comparison of erythema and induration as results of tuberculin tests. Int J Tuberc Lung Dis 2005 ; 9 (8) : 853-857
 
5) 森亨. ツベルクリン反応検査 3) ツベルクリン反応の計測 (2) 計測による誤差. In : 森亨. JATAブックス No.7 ツベルクリン反応検査. 東京 : 財団法人結核予防会, 1995 : 53-54
 
6) Perez-Stable EJ, Slutkin G. A demonstration of lack of variability among six tuberculin skin test readers. Am J Public Health 1985 ; 75 (11) : 1341-1343
 
7) Pouchot J, Grasland A, Collet C, et al. Reliability of tuberculin skin test measurement. Ann Intern Med 1997 ; 126 (3) : 210-214
 
8) Prezant DJ, Kelly KJ, Karwa ML, et al. Self-assessment of tuberculin skin test reactions by New York City firefighters : reliability and cost-effectiveness in an occupational health care setting. Ann Intern Med 1996 ; 125 (4) : 280-283
 
9) Ozuah PO, Burton W, Lerro KA, et al. Assessing the validity of tuberculin skin test readings by trained professionals and patients. Chest 1999 ; 116 (1) : 104-106
 
10) 日本結核病学会予防委員会. 今後のツベルクリン反応検査の暫定的技術的基準. (http://www.kekkaku.gr.jp/ga/ga-34.html) 日本結核病学会. 2006
 
11) Jordan TJ, Sunderam G, Thomas L, et al. Tuberculin reaction size measurement by the pen method compared to traditional palpation. Chest 1987 ; 92 (2) : 234-236
 
12) Bouros D, Zeros G, Panaretos C, et al. Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 1991 ; 99 (2) : 416-419
 
13) Wang L, Turner MO, Elwood RK, et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002 ; 57 (9) : 804-809
 
14) Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests : what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006 ; 10 (11) : 1192-1204
 
15) Bass JB. Tuberculin skin testing and other tests for latent tuberculosis infection. UpToDate 15.1. 2007
 
16) Latent tuberculosis. Dynamed. 2007
 
17) Rowland K, Guthmann R, Jamieson B. How should we manage a patient with a positive PPD and prior BCG vaccination? J Fam Pract 2006 ; 55 (8) : 718-720
 
P.282 掲載の参考文献
1) Bass JB Jr. Tuberculin skin testing and other tests for latent tuberculosis infection. UpToDate. 2007 ; 15. 2 2006 Dec 7 (cited 2007 Apr 20)
 
2) 日本結核病学会予防委員会. 今後のツベルクリン反応検査の暫定的技術的基準. 結核 2006 ; 81 : 387-391
 
3) Britton WJ, Gilbert GL, Wheatley J, et al. Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis. Tuberculosis (Edinb) 2005 ; 85 : 137-145
 
4) Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a Whole-Blood Interferon {gamma} Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium tuberculosis Infection. JAMA 2001 ; 286 : 1740-1747
 
5) Zahrani KA, Jahdali HA, Menzies D. Does Size Matter? Utility of Size of Tuberculin Reactions for the Diagnosis of Mycobacterial Disease. Am J Respir Crit Care Med 2000 ; 162 : 1419-1422
 
6) Wang L, Turner MO, Elwood RK, et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002 ; 57 : 804-809
 
7) Villarino ME, Burman W, Wang YC, et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA 1999 ; 281 : 169-171
 
8) Villarino ME, Brennan MJ, Nolan CM, et al. Comparison Testing of Current (PPD-S1) and Proposed (PPD-S2) Reference Tuberculin Standards. Am J Respir Crit Care Med 2000 ; 161 : 1167-1171
 
9) Molina-Gamboa JD, Ponce-de-Leon-Rosales S, Rivera-Morales I, et al. Evaluation of the sensitivity of RT-23 purified protein derivative for determining tuberculin reactivity in a group of health care workers. Clin Infect Dis 1994 ; 19 : 784-786
 
10) Toivgoogiin A, Toyota M, Yasuda N, et al. Validity of using tuberculin skin test erythema measurement for contact investigation during a tuberculosis outbreak in schoolchildren previously vaccinated with BCG. J Epidemiol 2005 ; 15 : 56-64
 
11) Menzies D. Interpretation of Repeated Tuberculin Tests. Boosting, Conversion, and Reversion. Am J Respir Crit Care Med 1999 ; 159 : 15-21
 
12) 泉慈子, 飯降聖子, 久郷敏明, 他. 医学部学生を対象としたツベルクリン反応検査解析結果からの考察. 結核 2006 ; 81 : 7-13
 
13) 重藤えり子, 前田晃宏, 大岩寛, 他. 看護学生における繰り返しツベルクリン反応 在学3年間の変動. 結核 2002 ; 77 : 659-664
 
14) 日野光紀, 小野靖, 小久保豊, 他. 医療関係者に対するツベルクリン反応及びBCG 接種歴調査と二段階ツベルクリン反応の検討. 結核 2002 ; 77 : 347-354
 
15) 安藤勝也, 山中克己, 明石都美. 一集団結核発生事例におけるツ反検査の意義. 結核 2002 ; 77 : 589-595
 
16) 大崎能伸, 武井 明. 医科大学生に対する二段階ツベルクリン反応検査の結果とその後の措置での問題点. 結核 2001 ; 76 : 685-689
 
P.285 掲載の参考文献
1) Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis : a systematic review. Lancet Infect Dis 2004 ; 4 (12) : 761-776
 
2) Mazurek GH, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005 ; 54 (RR-15) : 49-55
 
3) Mori T, et al. Specific detection of tuberculosis infection : an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004 ; 170 (1) : 59-64
 
4) Ravn P. The diagnostic potential of the QuantiFERON-RD1 test in patients with active tuberculosis. Abstract O411. Clin Microbiol Infect 2004 ; 10 (suppl 3) : 80
 
5) Brock I, et al. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004 ; 42 (6) : 2379-2387
 
6) Brock I, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004 ; 170 (1) : 65-69
 
7) Taggart EW, et al. Evaluation of an in vitro assay for interferon gamma production in response to the Mycobacterium tuberculosis-synthesized peptide antigens ESAT-6 and CFP-10 and the PPD skin test. Am J Clin Pathol 2006 ; 125 (3) : 467-473
 
8) Mazurek GH, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001 ; 286 (14) : 1740-1747
 
9) Harada N, et al. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006 ; 27 (5) : 442-448
 
10) Rolinck-Werninghaus C, et al. The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection. Eur J Pediatr 2003 ; 162 (7-8) : 534-536
 
11) Mori T, Harada N. Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. Kekkaku 2005 ; 80 (11) : 675-686
 
12) Diel R, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006 ; 28 (1) : 35-44
 
13) Bass JB. Tuberculin skin testing and other tests for latent tuberculosis infection. UpToDate(R) 14.2 2006 May 18, 2006 (cited 2006 July 18)
 
P.288 掲載の参考文献
1) Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005 ; 54 (RR-12) : 1-81
 
2) Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004 ; 350 (20) : 2060-2067
 
3) Comstock GW, Palmer CE. Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis 1966 ; 93 (2) : 171-183
 
4) Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970 ; 26 : 28-106
 
5) Comstock GW. Frost revisited : the modern epidemiology of tuberculosis. Am J Epidemiol 1975 ; 101 (5) : 363-382
 
6) Sepkowitz KA. AIDS, tuberculosis, and the health care worker. Clin Infect Dis 1995 ; 20 (2) : 232-242
 
7) Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989 ; 320 (9) : 545-550
 
8) Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1997 ; 126 (2) : 123-132
 
9) Efficacy of various durations of isoniazid preventive therapy for tuberculosis : five years of follow-up in the IUAT trial. Bulletin of the World Health Organization 1982 ; 60 (4) : 555-564
 
10) Palmer CE, Jablon S, Edwards PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc 1957 ; 76 (4) : 517-539
 
11) Westerholm P, Ahlmark A, Maasing R, et al. Silicosis and risk of lung cancer or lung tuberculosis : a cohort study. Environ Res 1986 ; 41 (1) : 339-350
PubMed
12) Paul R. Silicosis in Northern Rhodesia copper miners. Arch Environ Health 1961 ; 2 : 96-109
 
13) Chia S, Karim M, Elwood RK, et al. Risk of tuberculosis in dialysis patients : a population-based study. Int J Tuberc Lung Dis 1998 ; 2 (12) : 989-991
 
14) Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997 ; 87 (4) : 574-579
 
15) Snider DE Jr. Tuberculosis and gastrectomy. Chest 1985 ; 87 (4) : 414-415
 
16) Pickleman JR, Evans LS, Kane JM, et al. Tuberculosis after jejunoileal bypass for obesity. JAMA 1975 ; 234 (7) : 744
PubMed
17) Bruce RM, Wise L. Tuberculosis after jejunoileal bypass for obesity. Ann Intern Med 1977 ; 87 (5) : 574-576
 
18) Munoz P, Palomo J, Munoz R, et al. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995 ; 21 (2) : 398-402
 
19) Korner MM, Hirata N, Tenderich G, et al. Tuberculosis in heart transplant recipients. Chest 1997 ; 111 (2) : 365-369
 
20) Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients : report of five cases and review of the literature. Rev Infect Dis 1983 ; 5 (2) : 216-226
 
21) Feld R, Bodey GP, Groschel D. Mycobacteriosis in patients with malignant disease. Arch Intern Med 1976 ; 136 (1) : 67-70
 
22) Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer 1974 ; 33 (3) : 850-858
 
23) Schatz M, Patterson R, Kloner R, et al. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 1976 ; 84 (3) : 261-265
 
24) Bovornkitti S, Kangsadal P, Sathirapat P, et al. Reversion and reconversion rate of tuberculin skin reactions in correction with the use of prednisone. Dis Chest 1960 ; 38 : 51-55
 
25) Bateman ED. Is tuberculosis chemoprophylaxis necessary for patients receiving corticosteroids for respiratory disease? Respir Med 1993 ; 87 (7) : 485-487
 
26) Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998 ; 16 (1) : 9-13
 
27) Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002 ; 347 (23) : 1860-1866
 
28) Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000 ; 49 (RR-6) : 1-51
 
P.291 掲載の参考文献
1) Hopewell P. Tuberculosis. In : Mason RM, JF ; Brodddus, VC ; Nadel, JA, editor. Mason : Murray & Nadel's Textbook of Respiratory Medicine. 3rd ed. Philadelphia : Saunders ; 2000, 1086
 
2) Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis : A general review. Adv Tuberc Res 1970 ; 17 : 28-106
 
3) Bass JJ. Treatment of latent tuberculosis infection in HIV-negative patients. In : Rose B, editor. UpToDate. 15.1 ed. Waltham, MA : UpToDate ; 2007
 
4) Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000 ; 2 : CD001363
PubMed
P.294 掲載の参考文献
1) Ljungman P, et al. Definitions of cytomegalovirus infection and disease in transplant recipients. Clinical Infectious Diseases 2002 ; 34 : 1094-1097
 
2) Crawford SW, et al. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med 1988 ; 108 (2) : 180-185
 
3) Slavin MA, et al. Quantification of cytomegalovirus in bronchoalveolar lavage fluid after allogeneic marrow transplantation by centrifugation culture. J Clin Microbiol 1992 ; 30 (11) : 2776-2779
 
4) Cathomas G, et al. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood 1993 ; 81 (7) : 1909-1914
 
5) Goto H, et al. Rapid detection cytomegalovirus pneumonia in recipients of bone marrow transplant : evaluation and comparison of five survey methods for bronchoalveolar lavage fluid. Bone Marrow Transplant 1996 ; 17 (5) : 855-860
 
6) Sakamaki H, et al. Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation. Bone Marrow Transplant 1997 ; 20 (2) : 143-147
 
P.297 掲載の参考文献
1) Messori A, et al. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation : a meta-analysis. Bone Marrow Transplant 1994 ; 13 (2) : 163-167
 
2) Goodrich JM, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993 ; 118 (3) : 173-178
 
3) Ljungman P, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002 ; 99 (8) : 3050-3056
 
4) Winston DJ, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003 ; 26 (6) : 749-758
 
5) Winston DJ, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993 ; 118 (3) : 179-184
 
6) Couchoud C, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation : a meta-analysis. Transplantation 1998 ; 65 (5) : 641-647
 
7) Gourishankar S, et al. Meta-analysis of prophylaxis of CMV disease in solid organ transplantation : Is ganciclovir a superior agent to acyclovir? Transplantation Proceedings ; 33 : 1870-1872
 
8) Small LN, et al. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir : a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006 ; 43 (7) : 869-880
 
9) Guidelines for the preventing opportunistic infections among HIV-infected persons-2002, Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR 2002 ; 51 : (RR-8) : 1-52
 
10) Spector SA, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in person with AIDS. NEJM 1996 ; 334 (23) : 1491-1497
 
P.300 掲載の参考文献
1) Lesprit P, Scieux C, Lemann M, et al. Use of the cytomegalovirus (CMV) antigenemia assay for the rapid diagnosis of primary CMV infection in hospitalized adults. Clin Infect Dis 1998 ; 26 (3) : 646-650
 
2) Boivin G, Handfield J, Toma E, et al. Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects. J Clin Microbiol 1998 ; 36 (9) : 2509-2513
 
3) Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996 ; 34 (2) : 457-459
 
4) Blank BS, Meenhorst PL, Mulder JW, et al. Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol 2000 ; 38 (2) : 563-569
 
5) Hoshino Y, Nagata Y, Taguchi H, et al. Role of the cytomegalovirus (CMV) -antigenemia assay as a predictive and follow-up detection tool for CMV disease in AIDS patients. Microbiol Immunol 1999 ; 43 (10) : 959-965
 
6) Weinberg A, Hodges TN, Li S, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000 ; 38 (2) : 768-772
 
7) Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999 15 ; 68 (9) : 1305-1311 Boeckh M, Zaia JA, Jung D, et al. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 1998 ; 4 (1) : 13-19
 
8) van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991 ; 164 (2) : 265-270
 
9) van den Berg AP, van der Bij W, van Son WJ, et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation-a report of 130 consecutive patients. Transplantation 1989 ; 48 (6) : 991-995
 
10) Boeckh M, Bowden RA, Goodrich JM, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992 ; 80 (5) : 1358-1364
 
11) Yakushiji K, Gondo H, Kamezaki K, et al. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation : comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant 2002 ; 29 (7) : 599-606
 
12) Humar A, Lipton J, Welsh S, et al. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant 2001 ; 28 (5) : 485-490
 
13) Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation : a randomized double-blind study. Blood 1996 ; 88 (10) : 4063-4071
 
14) Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001 ; 33 (2) : 139-144
 
P.302 掲載の参考文献
1) 麻疹の現状と今後の麻疹対策について (平成14年10月) 国立感染症研究所 感染症情報センターホームページ
 
2) 2004年度感染症流行予測調査報告書 (感染症情報センターホームページ) http://idsc.nih.go.jp/yosoku/Annal-J/2004-06.pdf
 
3) Measles, Mumps, and Rubella-vaccine use and strategies for elimination of Measles, Mumps, and Rubella, and Congenital Rubella Syndrome and control of mumps. Rscommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 1998 ; 47 (RR-8) : 1-57 http://www.cdc.gov/mmwr/preview/mmwrhtml/00053391.htm
 
4) John C. An Evaluation of Measles Revaccination Among School-entry-aged Children. Pediatrics 1996 ; 97 : 613-618
 
5) Poland GA. Measles reimmunization in children seronegative after initial immunization. JAMA 1997 ; 777 (14) : 1156-1158
 
6) Lebaron CW. Persistence of MeaslesAntibodies After 2 Dose of Measles Vaccine in a Postelimination Enviroment. Arch Pediatr Adolesc Med 2007 ; 161 (3) : 294-301
 
7) Anders JF, Secondary failure rates of measles vaccines : a metaanalysis of published studies. Pediatr Infect Dis J 1996 ; 15 (1) : 62-66
 
8) Cohn ML. Measles vaccine failures : lack of sustained measles-specific immunoglobulin G in re vaccinated adolescents and young adults. Pediatr Infect Dis 1994 ; 13 (1) : 34-38
 
9) Markowitz LE. Persistence of measles antibody after revaccination. J Infect Dis 1992 ; 166 (1) : 205-208
 
10) Gans HA. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004 ; 190 : 83-90
 
P.305 掲載の参考文献
1) Albrecht MA. treatment and prevention of chickenpox. UpToDate ver 15. 1
 
2) Prevention of Varicella Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996 ; 45. RR-11
 
3) Mor M, et al. Efficacy of postexposure prophylaxis immunization with live attenuated varicella vaccine in the household setting-a pilot study. Vaccine 2004 ; 23 (3) : 325-328
 
4) Zaia JA, et al. Evaluation of varicella-zoster immune globulin : protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983 ; 147 : 737-743
 
5) Hanngren K, et al. Zoster immunoglobulin in varicella prophylaxis. A study among high-risk patients. Scand J Infect Dis 1983 ; 15 (4) : 327-334
 
6) A New Product (VariZIGTM) for Postexposure Prophylaxis of Varicella Available Under an Investigational New Drug Application Expanded Access Protocol. MMWR 2006 ; 55 (8)
PubMed
7) Asano Y, et al. Postexposure prophylaxis of varicella in family contacts by oral acyclovir. Pediatrics 1993 ; 92 : 219-222
 
8) Salzman MB, et al. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998 ; 17 : 256-257
 
9) Asano Y, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 1977 ; 59 : 3-7
 
10) Watson B, et al. Post-exposure effectiveness of varicella vaccine. Pediatrics 2000 ; 105 : 84-88
 
11) Prevention of Varicella Update Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999 ; 48. RR-6
 
P.308 掲載の参考文献
1) http://www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOME?CRETRY=1&SRETRY=0
 
2) Gonzalez ML, Usandizaga M, Alomar P, et al. Intradermal and intramuscular route for vaccination against hepatitis B. Vaccine 1990 ; 8 (4) : 402-405
 
3) Halliday ML, Rankin JG, Bristow NJ, et al. A randomized double-blind clinical trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine compared with a plasma-derived vaccine. Arch Intern Med 1990 ; 150 (6) : 1195-1200 (abstract only).
 
4) Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prevent Med 1998 ; 15 (1) : 1-8
 
5) Heijtink RA, Knol RM, Schalm SW. Low-dose (2 micrograms) hepatitis B vaccination inmedical students : comparable immunogenicity for intramuscular and intradermal routes. J Med Virol 1989 ; 27 (2) : 151-154
 
6) Henderson EA, Louie TJ, Ramotar K, et al. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infection Control and Hospital Epidemiology 2000 ; 21 (4) : 264-269
 
7) Oliveira PMC, Silva AE, Kemp VL, et al. Comparison of three different schedules of vaccination against hepatitis B in health care workers. Vaccine 1995 ; 13 (9) : 791-794
 
8) Pennie RA, O'Connor AM, Dulberg CS, et al. Low-cost hepatitis B vaccine improves uptake among self-paying health-care students. J Med Virol 1992 ; 37 (1) : 48-53
 
9) Winter AP, Follett EA, McIntyre J, et al. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994 ; 12 (9) : 771-772
 
10) Zuckerman JN. Hepatitis B third-generation vaccines : improved response and conventional vaccine non-response-third generation pre-S/S vaccines overcome non-response. J Viral Hepat 1998 ; 5 (Suppl 2) : 13-15
 
11) Zuckerman JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine : randomised double blind dose-response study. Brit Med J 1997 ; 314 (7077) : 329-333
PubMed
12) Patricia CJ, Patricia VF, Kenia E, et al. Randomized controlled trial of hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS research and therapy 2006 ; 3 : 9 (http://www.aidsrestherapy.com/content/3/1/9).
 
13) Rosman AS, Basu P, Galvin K, et al. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients : a randomized clinical trial. Am J Med 1997 ; 103 : 217-222
 
14) Daryani NE, Nassiri-Toosi M, Rashidi A, et al. Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection : a case-control study. World J of Gastroenterol 2007 ; 13 (2) : 294-298
 
15) Liu YL, Kao MT, Huang CC, et al. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005 ; 23 (30) : 3957-3960
 
16) http://www.who.int/vaccines/globalsummary/immunization/timeseries/tscoveragehepb3.htm
 
P.312 掲載の参考文献
1) McDermott AB, et al. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 1999 ; 17 : 330-339
 
2) Zuckerman JN, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not respond to standard vaccine : randomized double blind dose-response study. BMJ 1997 ; 314 : 329
PubMed
3) Hadler SC, et al. Long term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986 ; 315 : 209-214
 
4) Shapira MY, et al. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001 ; 34 : 123-127
 
5) Zuckerman JN. Hepatitis B third-generation vaccines : improved response and conventional vaccine non-response-third generation pre-S/S vaccines overcome non-response. J Viral Hepat 1998 ; 5 (suppl 2) : 13-15
 
6) Protection against hepatitis recommendations of the immunization practices advisory committee (ACIP). MMWR 1990 ; 39 : 1-26
 
7) Updated U.S. public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001 ; 50 : 1-42
 
P.315 掲載の参考文献
1) Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997 ; 26 : 43S-47S
 
2) Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003 ; 52 : 1-13, 5 ; quiz CE1-4
 
3) Chopra S. Diagnostic approach to hepatitis C virus infection.. UpToDate 15.1, 2006
 
4) Busch MP, Kleinman SH, Jackson B, et al. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases : Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000 ; 40 : 143-159
 
5) Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection : a perspective on long-term outcome. Semin Liver Dis 2000 ; 20 : 17-35
 
6) Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002 ; 36 : S65-73
 
7) Bresters D, Zaaijer HL, Cuypers HT, et al. Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients. Transfusion 1993 ; 33 : 634-638
 
8) Tobler LH, Stramer SL, Kleinman SH, et al. Misclassification of HCV-viremic blood donors as indeterminate by RIBA 3.0 because of human superoxide dismutase reactivity. Transfusion 2001 ; 41 : 1625-1626
 
9) Lamoril J, Lunel F, Laurent-Puig P, et al. Indeterminate third-generation recombinant immunoblot assay in hepatitis C virus infection. Group d'Etudes Moleculaires des Hepatites (GEMHEP). J Hepatol 1994 ; 21 : 133-134
 
10) Damen M, Zaaijer HL, Cuypers HT, et al. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995 ; 35 : 745-749
 
11) Gretch DR, dela Rosa C, Carithers RL Jr, et al. Assessment of hepatitis C viremia using molecular amplification technologies : correlations and clinical implications. Ann Intern Med 1995 ; 123 : 321-329
 
12) Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection : host, viral, and environmental factors. JAMA 2000 ; 284 : 450-456
PubMed
13) Scott JD, McMahon BJ, Bruden D, et al. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin Infect Dis 2006 ; 42 : 945-952
 
14) Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 ; 39 : 1147-1171
 
15) Yokosuka O, Kawai S, Suzuki Y, et al. Evaluation of clinical usefulness of second-generation HCV core antigen assay : comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0. Liver Int 2005 ; 25 : 1136-1141
 
16) Ravera G, Bottaro LC, Franceschini M, et al. Reliability and diagnostic use of a test for the search of the hepatitis C virus Ag (AgHCV). Hepatogastroenterology 2006 ; 53 : 753-756
 
17) Seme K, Poljak M, Babic DZ, et al. The role of core antigen detection in management of hepatitis C : a critical review. J Clin Virol 2005 ; 32 : 92-101
 
18) Krajden M, Shivji R, Gunadasa K, et al. Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol 2004 ; 42 : 4054-4059
 
19) Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001 ; 49 Suppl 1 : I1-21
 
20) Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection : a systematic review. JAMA 2007 ; 297 : 724-732
 

5章 感染症治療薬にかかわるエビデンス

P.320 掲載の参考文献
1) Fauci AS, et al. Harrison's Principles of Internal Medicine, 15th ed. USA, 2001 : 874
 
2) Lutsar I, et al. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 2000 ; 39 (5) : 335-343
 
3) 青木眞, 著 : レジデントのための感染症診療マニュアル, 東京 : 医学書院, 2000 : 16, 24, 161
 
4) David NG, et al. The Sanford Guide to Antimicrobial Therapy 2006, pp.59-63, USA, 2006
 
5) Prasad K, et al. Third generation cephalosporins versus conventional antibiotics for treating. acute bacterial meningitis. Cochrane Database Syst Rev 2004 ; (2) : CD001832. Review
PubMed
6) Overturf GD, et al. Comparative trial of carbenicillin and ampicillin therapy for purulent. Meningitis. Antimicrob Agents Chemother 1977 ; 11 (3) : 420-426
 
7) Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy 1998 ; 44 (2) : 142-147
 
8) Odio CM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999 ; 18 (7) : 581-590
 
9) Goldwater PN. Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. Int J Antimicrob Agents 2005 ; 26 (5) : 408-411, Epub 2005 Oct 7.
 
10) Bennett JE, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979 ; 301 (3) : 126-131
 
11) Larsen RA, et al. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990 ; 113 (3) : 183-187
 
12) Saag MS, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992 ; 326 (2) : 83-89
 
13) de Gans J, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992 ; 6 (2) : 185-190
 
14) Powderly WG, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992 ; 326 (12) : 793-798
 
15) van der Horst CM, et al. Treatment of cryptococcal meningitis associated with the acquired. immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997 ; 337 (1) : 15-21
 
16) Saag MS, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999 ; 28 (2) : 291-296
 
17) Brouwer AE, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis : a randomised trial. Lancet 2004 ; 363 (9423) : 1764-1767
 
P.325 掲載の参考文献
1) International Society of Anti-infective Pharmacology. http://www.isap.org/slides.htm.
 
2) Vella-Brincat JW, et al. Stability of benzylpenicillin during continuous home intravenous therapy. J Antimicrob Chemother 2004 ; 53 (4) : 675-677
 
3) Baririan N, et al. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51 (3) : 651-658
 
4) Rafati MR, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006 ; 28 (2) : 122-127
 
5) Grant EM, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002 ; 22 (4) : 471-483
 
6) Georges B, et al. Cefepime in critically ill patients : continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005 ; 43 (8) : 360-369
PubMed
7) Lorente L, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006 ; 40 (2) : 219-223
 
8) Eriksson U, et al. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours : randomised controlled trial. BMJ 2001 ; 322 (7286) : 579-582
PubMed
9) Bonow RO, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) : developed in collaboration with the Society of Cardiovascular Anesthesiologists : endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006 ; 114 (5) : e84-231
 
P.328 掲載の参考文献
1) Rowe JW, et al. The effect of age on creatinine clearance in men : a cross-sectional and longitudinal study. J Gerontol 1976 ; 3 : 155-163
 
2) Davis DF, et al. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950 ; 29 : 496-507
 
3) Mandell, Douglas, and Benett's Principles & Practice of Infectious Diseases. 5th ed. Churchill Livingstone 2000
 
4) Lindeman RD, et al. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985 ; 33 : 278-285
 
5) Cockcroft DW, et al. Prediction of creatinine clearance from serum creatinine. Nephron 1976 ; 26 : 31-41
 
6) Nicoll SR, et al. Assessment of creatinine clearance in healthy subjects over 65 years of age. Nephron 1991 ; 59 : 621-625
 
7) Fliser D, et al. Renal handling of drugs in the healthy elderly. Eur J Clin Pharmacol 1999 ; 55 : 205-211
 
8) Baracskay D, et al. Geriatric renal function : estimating glomerular filtration in an ambulatory elderly population. Clin Nephol 1997 ; 47 : 222-228
 
9) Fliser D, et al. Renal function in the elderly : Impact of hypertension and cardiac function. Kidney Int. 1997 ; 51 : 1196-1204
 
10) Fliser D, et al. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001 ; 37 : 79-83
 
11) Burkhardt H, et al. Creatinine clearance, Cockcroft-Gault formula, and cystatin C : Estimation of true glomerular filtration rate in the elderly. Gerontology 2002 ; 48 : 140-146
 
12) Lamb EJ, et al. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency : Is the Modification of Diet renal Disease formula an improvement? J Am Geriatr Soc 2003 ; 51 : 1012-1017
 
13) Van Den Noortgate NJ, et al. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc 2002 ; 50 : 1278-1282
 
14) Kampmann J, et al. Effect of some drug on penicillin half-life in blood. Clin Pharmacol Ther 1972 ; 13 (4) : 516-519
 
15) Farah F, et al. Hepatic drug acetylation and oxidation : effect of aging in men. BMJ 1977 ; 2 (6080) : 155-156
 
16) Guay DR, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Baysian forecaster. J Clin Pharmacol 1993 ; 33 : 918-922
 
17) Kampmann J, et al. The influence of renal function and some drugs on cephalosporin half-life in blood. In Edselius B. ed. Cephalosporin : Dimension and Future : Excerpta Medica. 1974
 
18) Barbhaiya RH. Effect of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother 1992 ; 36 : 1181-1185
 
19) Lumholtz B, et al Dose regimen of kanamycin and gentamcin. Acta Med Scand 1974 ; 196 (6) : 521-524
 
20) Vanhaeverbeek M, et al. Pharmacokinetics of once-daily amikacin in elderly patients. J Antimicrob Chemother 1993 ; 31 : 185-187
 
21) Nilsson-Ehle I, et al. Quinolone disposition in the elderly : practical implications. Drugs Aging 1991 ; 1 : 279-288
 
22) Chien SC, et al. Absence of age and gender effects on the pharmacokinetics of a single 500 mg oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997 ; 41 : 1562-1565
 
23) Miglioli PA, et al. Effect of age on single- and multiple-dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 1990 ; 39 : 161-164
 
24) Vartia KO, et al. Serum levels of antibiotics in young and old subjects following administration of dihydrostreptomycin and tetracycline. J Gerontol 1960 ; 15 : 392-394
 
25) Kramer PA, et al. Tetracycline absorption in elderly patients with achlorhydria. Clin Pharmacol Ther 1978 ; 23 (4) : 467-472
 
26) Baily WC, et al The effect of isoniazid on transaminase levels. Ann Intern Med 1974 : 81 (2) : 200-202
 
27) Loft S, et al. Metronidazole elimination is preserved in the elderly. Hum Exp Toxicol 1990 ; 9 : 155-159
 
P.332 掲載の参考文献
1) Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006 ; (1) : CD003344
PubMed
2) Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis in immunocompetent patients : systematic review and meta-analysis of randomized trials. BMJ 2004 ; 328 (7441) : 668
PubMed
3) Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance : a meta-analysis of randomized, controlied trials. Clin Infect Dis 2005 ; 41 : 149-158
 
4) Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999 ; 27 (suppl) : 24-28
 
5) Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patient with non-life-threatening infections. German and Austrian Imipenem/Cilastatin Study Group. Eur J Clin Microbiol Infect Dis 1992 ; 11 : 683-692
 
6) Gerecht WB, Henry NK, Hoffman WW, et al. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med 1989 ; 149 : 1279-1284
 
7) Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of sever infection in nonneutropenic patients. Antimicrob Agent Chemother 1994 ; 38 : 1309-1313
 
8) Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram negative infections. Antibiotic Study Group. Clin Infect Dis 1995 ; 20 : 1217-1228
 
9) Gribble MJ, Chow AW, Naiman SC, et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 1983 ; 24 : 388-393
 
10) Mandell LA, Nicolle LE, Ronald AR, et al. A prosective randomized trial of ceftazidime versus ceftazolin/tobramycin in the treatment of hospitalized patients with pneumonia. J Antimicrob Chemother 1987 ; 206 : 791-797
 
11) Cone LA, Woodard DR, Stoltzman DS, et al. Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. Antimicrob Agents Chemother 1985 ; 28 : 33-36
 
12) Croce MA, Fabian TC, Stewart RM, et al. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma 1993 ; 35 : 303-309
 
13) Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy : a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995 ; 15 (3) : 279-291. Review
PubMed
P.337 掲載の参考文献
1) CDC's Campaign to Prevent Antimicrobial Resistance (http://www.cdc.gov/drugresistance/healthcare/default.htm)
 
2) Defez C, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2005 ; 57 : 209-216
 
3) Harris AD, et al. Risk Factors for Imipenem-Resistant Pseudomonas aeruginosa among Hospitalized Patients. Clin Infect Dis 2002 ; 34 : 340-345
 
4) Georges B, et al. Risk of emergence of Pseudomonas aeruginosa resistance to β- lactam antibiotics in intensive care units. Crit Care Med 2006 ; 34 : 1636-1641
 
5) Gasink LB, et al. Fluoroquinolone-Resistant Pseudomonas aeruginosa : Assessment of Risk Factors and Clinical Impact. Am J Med 2006 ; 119 : 526. e19-25
 
6) Ohmagari N, et al. Risk Factors for Infections with Multidrug-Resistant Pseudomonas aeruginosa in Patients with Cancer. Cancer 2005 ; 104 : 205-212
 
7) Nseir S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005 ; 33 : 283-289
 
8) Harbarth S, et al. Parallel Analysis of Individual and Aggregated Data on Antibiotic Exposure and Resistance in Gram-Negative Bacilli. Clin Infect Dis 2001 ; 33 : 1462-1468
 
9) Cohen AE, et al. Fluoroquinolone-Resistant Escherichia coli in the Long-Term Care Setting. Am J Med 2006 ; 119 : 958-963
 
10) Guillemot D, et al. Low Dosage and Long treatment Duration of β-Lactam : risk factors for carriage of Penicillin-Resistant Streptococcus pneumoniae. JAMA 1998 ; 279 : 365-370
 
P.341 掲載の参考文献
1) Vogel T, et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women : a double-blind randomized controlled trial. CMAJ 2004 ; 170 (4) : 469-473
 
2) Talan DA, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. JAMA 2000 ; 283 : 1583-1590
 
3) Mombelli G, et al. Oral vs interavenous ciprofloxacine in the initial empirical management of severe pyelonephritis or complicated urinary tract infections : a prospective randomised clinical trial. Arch Intern Med 1999 ; 159 (1) : 53-58
 
4) Up to date Treatment of staphylococcal bacteremia in adults
 
5) Raad II, et al. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia : A study of 55 cases and review. Clin Infect Dis 1992 ; 14 : 75-82
 
6) Chang FY, et al. Staphylococcus aureus bacteremia : recurrence and impact of antibiotic treatment in a prospective multicenter study. Medicine 2003 ; 82 (5) : 333-339
 
7) Jensen AG, et al. Treatment and outcome of Staphylococcus aureus bacteremia. Arch Intern Med 2002 ; 162 : 25-32
 
8) Oosterheert JJ, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia : multicenter randomised trial. BMJ 2006 ; 333 : 1193
PubMed
9) Dunbar LM, et al. High-dose, short-course levofloxacin for a community- acquired pneumonia : a new treatment paradigm. Clin Infect Dis 2003 ; 37 : 752-760
 
10) Chastre J, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003 ; 290 : 2588-2598
 
P.343 掲載の参考文献
1) Uchiyama N, Aoshima M, Satoh T, et al. The efficacy of switch therapy in community-acquired pneumonia in Japan. Nihon Kokyuki Gakkai Zasshi 2003 ; 41 (4) : 261-267
 
2) Oosterheert JJ, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia : multicentre randomised trial. BMJ 2006 ; 333 (7580) : 1193. Epub 2006 Nov 7
 
3) Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia : duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998 ; 92 (8) : 1032-1039
 
4) Fernandez P, San Martin L, et al. Community acquired pneumonia : from intravenous to oral cephalosporin sequential therapy. Rev Med Chil 2000 ; 128 (3) : 267-272
 
5) Dagan R, Syrogiannopoulos G, Ashkenazi S, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994 ; 47 (suppl 3) : 43-51
 
6) Vilaichone A, Watana D, Chaiwatanarat T. Oral ceftibuten switch therapy for acute pyelonephritis in children. J Med Assoc Thai 2001 ; 84 (suppl 1) : S61-67
 
7) Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections. Arch Intern Med 1999 ; 159 (1) : 53-58
 
8) Wacha H, Warren B, Bassaris H, et al. Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections. Surg Infect (Larchmt) 2006 ; 7 (4) : 341-354
 
9) The Intra-Abdominal Infection Study Group. Solomkin JS, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996 ; 223 (3) : 303-315
 
10) Angeli P, Guarda S, Fasolato S, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis : similar efficacy at lower cost. Aliment Pharmacol Ther 2006 ; 23 (1) : 75-84
PubMed
11) Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 2000 ; 44 (12) : 3264-3271
 
12) Ahmetagic S, Jusufovic E, Cengic D, et al. Klinika za infektivne bolesti-Tuzla JZU UKC Tuzla. Analysis of amoxicillin-clavulanic acid (Xiclav) efficacy and the possibility of early switch from parenteral to oral therapy in the treatment of infections. Med Arh 2003 ; 57 (5-6) : 263-266
 
13) Guideline for the intravenous to oral switch of antibiotic therapyVersion・1.0 November 2006 www.nuh.nhs.uk/nch/antibiotics/Full%20Guidelines/iv%20switch%20policy%20FINAL07.pdf
 
14) Sevinca F, Prinsa JM, et al. Early switch from intravenous to oral antibiotics : guidelines and implementation in a large teaching hospital. Journal of Antimicrobial Chemotherapy1999 ; 43 : 601-606
 
15) http://www.idsociety.org/Content/NavigationMenu/Practice_Guidelines/Standards_Practice_Guidelines_Statements/Standards,_Practice_Guidelines,_and_Statements.htm
 
16) Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia : a meta-analysis. Arch Intern Med 2001 ; 161 (5) : 722-727
 
17) Patanwala AE, Erstad BL, Nix DE. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin 2007 ; 23 (1) : 185-193
 
18) Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev 2007 Oct 17 ; (4) : CD003237
 
P.347 掲載の参考文献
1) Saaq MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000 ; 30 : 710-718
 
2) Cox GM, Perfect JR. Cryptococcal meningoencephalitis in non-HIV-infected patients. 2007 UpToDate(R) (cited 2007 Apr 6)
 
3) Cox GM, Perfect JR. AIDS-associated cryptococcal meningoencephalitis. 2007 UpToDate(R) (cited 2007 Apr 6)
 
4) Powderly WG, Cloud GA, Dismukes WE, et al. Measurement of cryptococcal antigen in serum and cerebrospinal fluid : Value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994 ; 18 : 789-792
 
5) Lu H, Zhou Y, Yin Y, et al. Cryptococcal antigen test revisited : Significance for cryptococcal meningitis therapy monitoring in a tertiary Chinese hospital. J Clin Microbiol 2005 ; 43 : 2989-2990
 
6) Antinori S, Radice A, Galimberti L, et al. The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis. J Clin Microbiol 2005 ; 43 : 5828-5829
 
P.350 掲載の参考文献
1) Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia : Churchill Livingsone, 2004 ; 2402
 
2) Bryan CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. Chest 1997 ; 112 ; 1657-1664
 
3) CS Bryan. Treatment of Pneumococcal Pneumonia : The Case for Penicillin G. Am J Med 1999 ; 107 (1A) : 63S-68S
 
4) Austrian R. Pneumococcal infections. In : Isselbacher KJ, Braunwald E, Wilson JD, et al eds. Harrison's Principles of Internal Medicine, 13th ed. New York : McGraw-Hill, 1994 ; 607-611
 
5) Dale DC, Federman DD. Scientific American CD ROM 5. New York : Scientific American, 1996 : 7-12
 
6) Duma RJ. Pneumococcal pneumonia. In : Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia : WB Saunders, 1996 : 1569-1576
 
7) Musher DM. Streptococcus pneumoniae. In : Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York : Churchill-Livingstone, 1995 : 1811-1826
 
8) Seaton A, Seaton D, Leitch AG. Pneumonia. In : Seaton A, Seaton D, Leitch AG, eds. Crofton and Douglas's Respiratory Diseases, 4th ed. Oxford : Blackwell Scientific Publications, 1989 : 285-345
 
9) Johnson CC, Finegold SM. Pyogenic bacterial pneumonia. Textbook of Respiratory Medicine, 2nd ed. Philadelphia : WB Saunders, 1994 : 1036-1093
 
10) Berkow R, Fletcher AJ, eds. The Merck Manual of Diagnosis and therapy, 16th ed. Rahway, NJ : Merck Research Laboratories, 1992 : 684
 
11) Henkel TJ, Fraser VJ. Treatment of infectious diseases. In : Ewald GA, McKenzie CR, eds. Manual of Medical Therapeutics, 28th ed. Boston : Little Brown, 1995 : 297-326
 
12) Lipchik RJ. Pneumonia. In : Noble J, Green HL, Levinson W, et al eds. Textbook of Primary Care Medicine, 2nd ed. St. Louis : Mosby, 1996 : 1531-1540
 
13) Greenwood BM. Pneumococcal infection. In : Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine, 3rd ed. Oxford : Oxford University Press, 1996 : 511-523
 
14) Weiser JN. Pneumococcus. In : Schlossberg P, ed. Current Therapy of Infectious Diseases. St. Louis : Mosby, 1996 : 443-446
 
15) Niederman MS, Sarosi GA. Respiratory tract infections. In : George RB, Light RW, Matthay MA, et al eds. Chest Medicine : Essentials of Pulmonary and Critical care Medicine, 3rd ed. Baltimore : Williams & Wilkins, 1995 : 423-478
 
16) Isada CM, Katsen BL, Goldman MP, et al. Infectious Disease Handbook, 2nd ed. Cleveland : Lexi-Comp, 1996 ; 254 : 739-740
 
P.352 掲載の参考文献
1) Lin RY. A perspective on penicillin allergy. Arch Intern Med 1992 ; 152 : 930-937
 
2) Romano A, Gueant-Rodriguez R, Viola M, et al. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004 ; 141 : 16-22
 
3) Pichichero M, Casey J. Safe use of selected cephalosporins in penicillin-allergic patients : A meta-analysis. Otolaryngology-Head and Neck Surgery 2007 ; 136 : 340-347
 
4) McConnell S, Penzak S, Warmack T, et al. Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy. Clin Infect Dis 2000 ; 31 : 1512-1514
 
5) Sodhi M, Axtell S, Callahan J, et al. Is it safe to use carbapenems in patients with a history of allergy to penicillin. J Antimicrob Chemother 2004 ; 54 : 1155-1157
 
6) Romano A, Viola M, Gueant-Rodriguez R, et al. Brief communication : Tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med 2007 ; 146 : 266-269
 
7) Romano A, Viola M, Gueant-Rodriguez R, et al. Imipenem in patients with immmediate hypersensitivity to penicllins. N Engl J Med 2006 ; 26 : 2835-2837
 
8) Saxon A, Adelman D, Patel A, et al. Imipenem cross-reactivity with penicillin in humans J Allergy Clin Immunol 1988 ; 82 : 213-217
 
9) Prescott W, DePedtel D, Ellis J, et al. Incidence of carbapenems-associated allergic-type reactions among patients with versus patients without a reported allergy. Clin Infect Dis 2004 ; 38 : 1102-1107
 
P.355 掲載の参考文献
1) Craig WA. Pharmacokinetic/pharmacodynamic parameters : Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998 ; 26 : 1-12
 
2) Freeman CD, et al. Once-daily dosing of aminoglycosides : Review and recommmendations for clinical practice. J Antimicrob Chemother 1997 ; 39 : 677
 
3) Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am 2003 ; 17 : 503-528
 
4) Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989 ; 24 : 281-293
 
5) Nicolau DP, et al. Once-daily aminoglycoside dosing : impact on requests and costs for therapeutic drug monitoring 1996 ; 18 : 263-266
 
6) Parker SE, Davey PG. Once-daily aminoglycoside administration in Gram-negative sepsis : economic and practical aspects. Pharmacoeconomics 1995 ; 7 : 393-402
 
7) Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults A meta-analysis. Ann Intern Med 1996 ; 124 : 717-725
 
8) Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997 ; 24 : 796-809
 
9) Raz R, Adawi M, Romano S. Intravenous administration of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995 ; 14 : 88-91
 
10) Prins JM, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993 ; 341 : 335-339
 
11) 白松幸爾, 他. Jap J Antibiotics 1983 ; 36 : 81
 
12) Drew RH. Consolidated once-daily aminoglycoside dosing with gentamicin and tobramycin UpToDate 12.3
 
P.358 掲載の参考文献
1) 17. Drug allergy part B : Allergic reaction to individual drugs, low molecular weight. In : Paterson's Allergic Disease, 6th ed. Lippincott Williams & Wilkins, 2002 : 345-347
 
(1) Roujeau JC, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995 ; 333 : 1600-1607
 
2) Solenski R. Drug desensitization. Immunol Allergy Clin North Am 2004 ; 24 : 425-443
 
(2) Chung WH, et al. A marker for Stevens-Johnson syndrome. Nature 2004 ; 428 : 486
PubMed
3) スルファメトキサゾール・トリメトプリム配合剤の副作用. 医薬品副作用情報 第11分冊 No71-No80 薬務公務社
 
(3) Mallal S, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008 ; 358 : 568-579
 
(4) Caumes E, et al. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997 ; 133 : 465-469
 
4) Masters PA, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003 ; 163 : 402-410
 
5) Koizumi A, et al. Evidence on N-acetyltransferase allele-associated metabolism of hydrazine in Japanese workers. J Occup Environ Med 1998 ; 40 (3) : 217-222
 
6) 菊池嘉. ST合剤によるカリニ肺炎予防投与中に皮疹を生じた症例に対する, ST合剤の減感作療法. 治療学 (0386-8109) 2001 ; 35 (2) : 221-223
 
7) 野崎威功真. 脱感作によりST合剤 (T/S) で治療が可能であった, T/S 過敏症カリニ肺炎の1女児例. 日本小児科学会雑誌 (0001-6543) 2005 ; 109 (2) : 269
 
8) Bonfanti P, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX : a randomized multicentric study. Biomed Pharmacother 2000 ; 54 : 45-49
 
9) Straatmann A, et al. A randomized, pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides. Braz J Infect Dis 2002 ; 6 (6) : 276-280. Epub 2003 Nov 3.
 
10) Leoung GS, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001 ; 184 (8) : 992-997. Epub 2001 Sep 4.
 
11) Rich JD, et al. Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997 ; 79 (5) : 409-414
 
P.362 掲載の参考文献
1) Naber KG, Allin DM, Clarysse L, et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 2004 ; 23 (6) : 596-605
PubMed
2) Dean NC, Sperry P, Wikler M, et al. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. Antimicrob Agents Chemother 2006 ; 50 (4) : 1164-1169
 
3) Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001 ; 119 (5) : 1439-1448
 
4) Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006 ; 354 : 1352-1361
 
5) Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005 ; 41 (9) : 1269-1276, Epub 2005 Sep 28
 

6章 Special topics編

P.368 掲載の参考文献
1) Recommended Immunization Schedules for Persons Aged 0-18 Years-United States, 2007. CDC ; MMWR January 5, 2007/55 ; Q1-Q4
 
2) Cook IF, et al. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2006 ; 24 : 2395-2402
PubMed
3) Mark A, et al. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999 ; 17 : 2067-2072
 
4) Dennehy PH, et al. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics 1991 ; 88 : 604-607
 
5) Wahl M, et al. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine : side effects and antibody response. Scand J Infect Dis 1987 ; 19 : 617-621
PubMed
6) Belshe RB, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004 ; 351 : 2286-2294
 
7) Kenney RT, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004 ; 351 : 2295-2301
 
8) Auewarakul P, et al. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007 ; 25 : 659-663
 
P.372 掲載の参考文献
1) Centers for Disease Control and Prevention. General Recommendations on Immunization : recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2006 ; 55 (RR-15)
 
2) King GE, Hadler SC. Simultaneous administration of childhood vaccines : an important public health policy that is safe and efficacious. Pediatr Infect Dis 1994 ; 13 (5) : 394-407
 
3) Deforest A, Long SS, Lischner HW, et al. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 1988 ; 81 (2) : 237-246
 
4) Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Pediatr Infect Dis J 1998 ; 17 (11) : 980-985
 
5) Giammanco G, Li Volti S, Mauro L, et al. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine 1991 ; 9 (10) : 747-750
 
P.376 掲載の参考文献
1) Guidelines for vaccinating pregnant women. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Atlanta, Ga. : Centers for Disease Control and Prevention, 2002
 
2) 予防接種ガイドライン等検討委員会. 予防接種ガイドライン 2006年3月改訂版
 
3) CDC. Notice to readers : revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR 2001 ; 50 (No. 49) : 1117
 
4) Munoz FM, Englund JA. A step ahead. Infant protection through maternal immunization. Pediatr Clin North Am 2000 ; 47 : 449-463
 
5) Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps : recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1998 ; 47 (RR-8) : 1-57
 
6) Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1996 ; 45 (RR-11) : 1-36
 
7) Update on adult immunization. Recommendations of the immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1991 ; 40 (RR-12) : 1-94
 
8) Atkinson W. Epidemiology and Prevention of Vaccine-Preventable Disease, 7th ed. Atlanta, Ga. : Centers for Disease Control and Prevention, 2002
 
9) Bridges CB, Fukuda K, Cox NJ, et al. Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002 ; 51 (RR-3) : 1-31
 
10) The role of BCG vaccine in the prevention and control of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1996 ; 45 (RR-4) : 1-18
 
P.379 掲載の参考文献
1) Boyce JM, et al. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002 ; 51 (RR-16) : 1-45, quiz CE1-4
 
2) Larson E, et al. A causal link between handwashing and risk of infection? Examination of the evidence. Infect Control Hosp Epidemiol 1988 ; 9 (1) : 28-36
 
3) Curtis V, et al. Effect of washing hands with soap on diarrhoea risk in the community : a systematic review. Lancet Infect Dis 2003 ; 3 (5) : 275-281
 
4) Meadows E, et al. A systematic review of the effectiveness of antimicrobial rinse-free hand sanitizers for prevention of illness-related absenteeism in elementary school children. BMC Public Health 2004 ; 4 : 50
 
5) Rabie T, et al. Handwashing and risk of respiratory infections : a quantitative systematic review. Trop Med Int Health 2006 ; 11 (3) : 258-267
 
6) Larson EL, et al. Effect of antibacterial home cleaning and handwashing products on infectious disease symptoms : a randomized, double-blind trial. Ann Intern Med 2004 ; 140 (5) : 321-329
 
7) Luby SP, et al. Effect of intensive handwashing promotion on childhood diarrhea in high-risk communities in Pakistan : a randomized controlled trial. JAMA 2004 ; 291 (21) : 2547-2554
 
8) Sandora TJ, et al. A randomized, controlled trial of a multifaceted intervention including alcohol-based hand sanitizer and hand-hygiene education to reduce illness transmission in the home. Pediatrics 2005 ; 116 (3) : 587-594
 
9) Larson EL, et al. Effect of antiseptic handwashing vs alcohol sanitizer on health care-associated infections in neonatal intensive care units. Arch Pediatri Adolesc Med 2005 ; 159 (4) : 377-383
 
10) Duizer E, et al. Inactivationof calicivirus. Appl Environ Microbiol 2004 ; 70 (8) : 4538-4543
 
P.382 掲載の参考文献
1) Guideline for Isolation Precautions in Hospitals. Julia S. Garner, RN, MN, and the Hospital Infection Control Practices Advisory Committee From the Public Health Service, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Georgia. Garner JS, Hospital Infection Control Practices Advisory Commitee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996 ; 17 : 53-80, and Am J Infect Control 1996 ; 24 : 24-52
 
2) Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS) Version 2/3. May 3, 2005
 
3) Center for Disease Control. Recommendations for prevention of HIV transmission in health-care settings. MMWR 1987 ; 36 (2S) : 1S-18S
 
4) Centers for Disease Control. Update : universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988 ; 37 : 377-382, 387-388
 
5) Lynch P, Jackson MM, Cummings MJ, et al. Rethinking the role of isolation practices in the prevention of nosocomial infections. Ann Intern Med 1987 ; 107 : 245-246
 
6) Department of Labor, Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens ; final rule. Federal Register 1991 ; 56 (235) : 64175-64182
 
P.385 掲載の参考文献
1) Hota B. Contamination, Disinfection, and Cross-Colonization : Are Hospital Surfaces Reservoirs for Nosocomial Infection? Clinical Infectious Diseases 2004 ; 39 : 1182-1189
 
2) Marinella MA, Pierson C, Chenoweth C. The stethoscope. A potential source of nosocomial infection? Arch Intern Med 1997 ; 157 (7) : 786-790
 
3) Jones JS, Hoerle D, Riekse R. Stethoscopes : a potential vector of infection? Ann Emerg Med 1995 ; 26 (3) : 296-299
 
4) Parmar RC, Valvi CC, Sira P, et al. A prospective, randomised, double-blind study of comparative efficacy of immediate versus daily cleaning of stethoscope using 66% ethyl alcohol. Indian J Med Sci 2004 ; 58 (10) : 423-430
 
5) Steven N, Urban C, Mangini ED, et al. "Is the Clinicians' Necktie a Potential Fomite for Hospital Acquired Infections?" Paper presented at the 104th General Meeting of the American Society for Microbiology May 23-27 2004, New Orleans, Louisiana, p. 204
 
6) McLure HA, Mannam M, Talboys CA, et al. The effect of facial hair and sex on the dispersal of bacteria below a masked subject. Anaesthesia 2000 ; 55 (2) : 173-176
 
7) Waterman TR, Smeak DD, Kowalski J, et al. Comparison of bacterial counts in glove juice of surgeons wearing smooth band rings versus those without rings. Am J Infect Control 2006 ; 34 (7) : 421-425
 
8) Laterality. Orientation of the stethoscope around the neck : a random phenomenon or an indicator of cerebral lateralisation? Cross-sectional survey 2006 ; 11 (3) : 287-293
 
9) Roger Dobson Doctors should abandon ties and avoid nose rings. BMJ 2003 ; 326 : 1231
 
CDCガイドライン CDC病院における隔離予防策ガイドライン Guideline for Isolation Precautions in Hospitals. Infect Control Hosp Epidemiol 1996 ; 17 : 53-80, and Am J Infect Control 1996 ; 24 : 24-52
 
CDC手術部位感染予防ガイドライン Guideline for the Prevention of Surgical Site Infection, 1999 http://www.cdc.gov/ncidod/dhqp/gl_surgicalsite.html
 
CDC手指衛生ガイドライン Guideline for Hand Hygiene in Healthcare Settings-2002 http://www.cdc.gov/ncidod/dhqp/gl_handhygiene.html
 
P.387 掲載の参考文献
1) CDC. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR 2001 ; 50 (RR--11) : 1-42
 
2) CDC. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR 2005 ; 54 (RR--9) : 1-18
 
3) Guideline for Isolation Precautions : Preventing Transmission of Infectious Agents in Healthcare Settings 2007 http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf
 
4) A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. MMWR 2006 ; 55 (RR--16) : 1-40
 
5) Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. MMWR 1998 ; 47 (RR-19) : 1-54
 
6) 厚生労働省. B型肝炎について一般的なQ&A 2006. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/01.pdf
 
7) 厚生労働省. C型肝炎について一般的なQ&A 2006 http://www.med.or.jp/kansen/bandc/cqa.pdf
 
8) CDC. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings. MMWR 2006 ; 55 (RR--14) : 1-17
 
P.389 掲載の参考文献
1) 植田浩司. ムンプス. In : 楠智一, 他編集. 必修小児科学, 改訂第2版. 東京 : 南江堂, 1985 : 352
 
2) 水原春郎. 風疹. In : 楠智一, 他編集. 必修小児科学, 改訂第2版. 東京 : 南江堂, 1985 : 333-334
 
3) 水原春郎. 麻疹. In : 楠智一, 他編集, 必修小児科学, 改訂第2版. 東京 : 南江堂, 1985 : 331-333
 
4) 水原春郎. 水痘. In : 楠智一, 他編集. 必修小児科学, 改訂第2版. 東京 : 南江堂, 1985 : 334-335
 
5) Litman N. Mumps virus. In : Mandell GL, et al eds. Principles and Practice of Infectious Diseases, 6th ed. Philadelphia : Churchill Livingstone, 2005 : 2003-2008
 
6) Gershon AA. Mumps. In : Gershon AA, et al eds. Krugman's Infectious Diseases of Children, 11th ed. Philadelphia : Mosby, 2004 : 391-401
 
7) Hay CM. Rubella. UpToDate(R) 15.1 2006 (cited 2007 May 5)
 
8) Gershon AA. Rubella virus. In : Mandell GL, et al eds. Principles and Practice of Infectious Diseases, 6th ed. Philadelphia : Churchill Livingstone, 2005 : 1921-1926
 
9) Gershon AA. Rubella. In : Gershon AA, et al eds. Krugman's Infectious Diseases of Children, 11th ed. Philadelphia : Mosby, 2004 : 531-543
 
10) Barinaga JL. Epidemiology and transmission of measeles. UpToDate(R) 15.1 2007 (cited 2007 May 5)
 
11) Barinaga JL. Clinical presentation and diagnosis of measles. UpToDate(R) 15.1 2006 (cited 2007 May 5)
 
12) Gershon AA. Measles Virus. In : Mandell GL, et al eds. Principles and Practice of Infectious Diseases, 6th ed. Philadelphia : Churchill Livingstone, 2005 : 2031-2038
 
13) Katz SL. Measles. In : Gershon AA, et al eds. Krugman's Infectious Diseases of Children, 11th ed. Philadelphia : Mosby, 2004 : 353-371
 
14) Albrecht MA. Clinical features of varicella-zoster virus infection : Chikenpox. UpToDate(R) 15.1 2006 (cited 2007 May 5)
 
15) Hall S. Second Varicella infections : Are they more common than previously thought? Pediatrics 2002 ; 109 : 1068-1073
 
16) Gershon AA. Varicella-zoster virus infections. In : Gershon AA, et al eds. Krugman's Infectious Diseases of Children, 11th ed. Philadelphia : Mosby, 2004 : 785-816
 
P.391 掲載の参考文献
1) 厚生労働省, 大量調理施設衛生管理マニュアル, 平成9年3月24日衛食第85号別添) (最終改正 : 平成15年8月29日食安発第0829008号) http://www.mhlw.go.jp/topics/syokuchu/kanren/yobou/dl/manual.pdf
 
2) 古谷信彦, 山口惠三. 栄養関係者が知っておくべき感染症. 臨床病理レビュー特集 2003 ; 127 : 105-111
 
3) Khuri-Bulos NA, Abu Khalaf M, Shehabi A, et al. Foodhandler-associated Salmonella outbreak in a university hospital despite routine surveillance cultures of kitchen employees. Infect Control Hosp Epidemiol 1994 ; 15 (5) : 311-314
 
4) L'Ecuyer PB, Diego J, Murphy D, et al. Nosocomial outbreak of gastroenteritis due to Salmonella senftenberg. Clin Infect Dis 1996 ; 23 (4) : 734-742
 
5) Molina-Gamboa JD, Ponce-de-Leon-Rosales S, Guerrero-Almeida ML, et al. Salmonella gastroenteritis outbreak among workers from a tertiary care hospital in Mexico City. Rev Invest Clin 1997 ; 49 (5) : 349-353
 
6) Standaert SM, Hutcheson RH, Schaffner W. Nosocomial transmission of Salmonella gastroenteritis to laundry workers in a nursing home. Infect Control Hosp Epidemiol 1994 ; 15 (1) : 22-26
 
7) Gopal Rao G, Ozerek A, Jeanes A, et al. Detection of a nosocomial outbreak of salmonellosis may be delayed by application of a protocol for rejection of stool cultures. J Hosp Infect 2004 ; 56 (4) : 327
PubMed
8) 厚生労働省, 平成13年食中毒発生状況, 食中毒・食品監視関連情報, http://www.mhlw.go.jp/topics/syokuchu/01hassei/1.html
 
9) 工藤泰雄. 腸管感染症・食中毒-最近の動向. 総合臨床 2005 ; 54 : 2421-2428
 
10) Shannon RJ. Dietary Depertment, Chapter 105, Infection Control and Applied Epidemiology, Principles and Practice, APIC, Mosby, 1996
 
11) FDA, HAZARD ANALYSIS AND CRITICAL CONTROL POINTPRINCIPLES AND APPLICATION GUIDELINES, 1997 http://www.cfsan.fda.gov/~comm/nacmcfp.html
 
12) JIFSAN Good Aquacultural Practices Program : Prerequisite Programs for Good Manufacturing Practices (GMPs) http://www.life.umd.edu/grad/MLfsc/8%20%20Good%20Manufacturing%20Practices%20(GMPs)%20.pdf
 
P.394 掲載の参考文献
1) D'Angelo LJ, Hierholzer JC, Holman RC, et al. Epidemic keratoconjunctivitis caused by adenovirus type 8 : epidemiologic and laboratory aspects of a large outbreak. Am J Epidemiol 1981 ; 113 : 44-49
 
2) Richmond S, Burman R, Crosdale E, et al. A large outbreak of keratoconjunctivitis due to adenovirus type 8. Journal of Hygiene 1984 ; 93 : 285-291
 
3) Koo D, Bouvier B, Wesley M, et al. Epidemic keratoconjunctivitis in a university medical center ophthalmology clinic ; need for re-evaluation of the design and disinfection of instruments. Infect Control Hosp Epidemiol 1989 ; 10 : 547-552
 
4) Birenbaum E, Linder N, Varsano N, et al. Adenovirus type 8 conjunctivitis outbreak in a neonatal intensive care unit. Arch Dis Child 1993 ; 68 : 610-611
 
5) Flomenberg P. Epidemiology and clinical manifestations of adenovirus infection. UpToDate(R) 15.2. 2006 Dec 21, 2006 (cited 2007. May 10)
 
6) Jacobs D. Conjunctivitis. UpToDate(R) 15.2. 2006 Dec 15, 2006 (cited 2007. May 10)
 
7) 青木功喜, 井上幸次, ウイルス性結膜炎のガイドライン作成委員会. 【ウイルス性結膜炎のガイドライン】第3章 臨床像. 日本眼科学会雑誌 2003 ; 1 : 11-16
 
8) Gottsch JD. Surveillance and control of epidemic keratoconjunctivitis. Transactions of the American Ophthalmological Society 1996 ; 94 : 539-587
 
9) Buffington J, Chapman LE, Stobierski MG, et al. Epidemic keratoconjunctivitis in a chronic care facility : risk factors and measures for control. J Am Geriatr Soc 1993 ; 41 : 1177-1181
 
10) Roba LA, Kowalski RP, Gordon AT, et al. Adenoviral ocular isolates demonstrate serotype-dependent differences in in vitro infectivity titers and clinical course. Cornea 1995 ; 14 : 388-393
 
11) Azar MJ, Dhaliwal DK, Bower KS, et al. Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Am J Ophthalmol 1996 ; 121 : 711-712
 
12) Jernigan JA, Lowry BS, Hayden FG, et al. Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic : risk factors and control. J Infect Dis 1993 ; 167 : 1307-1313
 
13) Flomenberg P, Kojaoghlanian T. Diagnosis and treatment of adenovirus infection in adults. UpToDate(R) 15.2. 2006 Jul 25, 2006 (cited 2007. May 20)
 
14) Kinchington PR, Turse SE, Kowalski RP, et al. Use of polymerase chain amplification reaction for the detection of adenoviruses in ocular swab specimens. Invest Ophthalmol Vis Sci 1994 ; 35 : 4126-4134
 
15) Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis-a double-blind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther 2005 ; 21 : 157-165
 
16) Hillenkamp J, Reinhard T, Ross RS, et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine : a controlled clinical pilot study. Arch Ophthalmol 2001 ; 119 : 1487-1491
 
17) Rutala WA, Peacock JE, Gergen MF, et al. Efficacy of hospital germicides against adenovirus 8, a common cause of epidemic keratoconjunctivitis in health care facilities. Antimicrob Agents Chemother 2006 ; 50 : 1419-1424
 
P.396 掲載の参考文献
1) Antimicrobial prophylaxis for surgery. Treatment Guidelines from the Medical Letter (www.medicalletter.org) 2004 ; 2 : 27-32
 
2) Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002 ; 123 : 326-332
 
3) Azner R, Mateu M, Miro M, et al. Antibiotic prophylaxis in non-cardiac thoracic surgery : cefazolin versus placebo. Eur J Cardiothorac Surg 1991 ; 5 : 515-518
 
4) Perez AR, Roxas MF, Hivano SS, et al. A randomized, double-blind, placebo-controlled trial to determine effectiveness of antibiotic prophylaxis for tension-free mesh herniorrhaphy. J Am Coll Surg 2005 ; 200 : 393-398
 
5) Kuzu MA, Hazinedaroglu S, Dolalan S, et al. Prevention of surgical site infection after open prothetic inguinal hernia repair : efficacy of parental versus oral prophylaxis with amoxicillin-clavulanic acid in a randomized clinical trial. World J Surg 2005 ; 29 : 794-799
 
6) Ahmad I, Mouncher A, Abdoolah A, et al. Antibiotic prophylaxis for percutaneous endoscopic gastrostomy-a prospective, randomized, double-blind trial. Aliment Pharmacol Ther 2003 ; 18 : 209-215
 
7) Saadeddin A, Freshwater DA, Fisher NC, et al. Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non-malignant conditions : a double-blind prospective randomized controlled trial. Aliment Pharmacol Ther 2005 ; 22 : 565-570
 
8) Adriano T, Luca L, Gianluca C, et al. The need for antibiotic prophylaxis in elective laparoscopic cholecystectomy : a prospective randomized study. Arch Surg 2000 ; 135 : 67-70
 
9) Chang WT, Lee KT, Chuang SC, et al. The impact of prophylactic antibiotics on postoperative infection complication in elective laparoscopic cholecystectomy : a prospective randomized study. Am J Surg 2006 ; 191 : 721-725
 
10) Lewis RT. Oral versus systemic antibiotic prophylaxis in elective colon surgery : a randomized study and meta-analysis send a message from the 1990s. Can J Surg 2002 ; 45 : 173-180
 
11) Byl B, Deviere J, Struelens MJ, et al. Antibiotic prophylaxis for infectious complications after therapeutic endoscopic retrograde cholangiopancreatography : a randomized, double-blind, placebo-controlled study. Clin Infect Dis 1995 ; 20 : 1236-1240
 
12) van den Hazel SJ, Speelman P, Dankert J, et al. Piperacillin to prevent cholangitis after retrograde cholangiopancreatography. A randomized controlled trial. Ann Intern Med 1996 ; 125 : 442-447
 
13) Gadallah MF, Ramdeen G, Mignone J, et al. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheter. Am J Kidney Dis 2000 ; 36 : 1014-1019
 
14) Wazait HD, Patel HR, van der Meulen JH, et al. A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection : the pitfalls of ciprofloxacin. BJU Int 2004 ; 94 : 1048-1050
 
15) Bolon MK, Morlote M, Weber SG, et al. Glycopeptides are no more effective than β-lactam agents for prevention of surgical site infection after cardiac surgery : a meta-analysis. Clin Infect Dis 2004 ; 38 : 1357-1363
 
16) Cunningham M, Bunn F, Handscomb K. Prophylactic antibiotics to prevent surgical site infection after breast surgery. Cochrane Database Syst Rev 2006 ; (2) : CD005360
PubMed
17) Sanchez-Manuel FJ, Seco-Gil JL. Antibiotic prophylaxis for hernia repair. Cochrane Database Syst Rev 2004 ; (4) : CD003769
 
18) Costa AD, Kirkorian G, Cucherat M, et al. Antibiotics prophylaxis for permanent pacemaker implantation : a meta-analysis. Circulation 1998 ; 97 : 1796-1801
 
19) Harbarth S, Samore MH, Lichtenberg D, et al. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infection and antimicrobial resistance. Circulation 2000 ; 101 : 2916-2921
 
20) Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis 2001 ; 7 : 828-831
 
21) Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 2004 ; 15 : 547-556
 
22) Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery : an advisory statement from the national surgical infection prevention project. Clin Infect Dis 2004 ; 38 : 1706-1715
 
23) Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Am J Infect Control 1999 ; 27 : 97-134
 
P.401 掲載の参考文献
1) Murray PR (Editor in chief). Manual of Clinical Microbiology, 8th ed. Washington DC : ASM Press, 2003
 
2) Infectious Diseases Society of America. Policy statement on consolidation of clinical microbiology laboratories. Clin Infect Dis 2001 ; 32 : 604
 
3) Peterson LR, Hamilton JD, Baron EJ, et al. Role of clinical microbiology laboratories in the management and control of infectious diseases and the delivery of health care. Clin Infect Dis 2001 ; 32 : 605-611
 
4) Procop GW, Winn W. Outsoursing microbiology and offsite laboratories : Implication on patient care, cost savings, and graduate medical education. Arch Pathol Lab Med 2003 ; 127 : 623-624
 
5) Van Eldere J. Changing needs, opportunities and constraints for the 21st century microbiology laboratory. Clin Microbiol Infect 2005 ; 11 (suppl 1) : 15-18
 
6) Church DL, Don-Joe C, Unger B. Effects of restructuring on the performance of microbiology laboratories in Alberta. Arch Pathol Lab Med 2000 ; 124 : 357-361
 
7) Carter E, Stubbs JR, Bennett B. A model for consolidation of clinical microbiology laboratory services within a multihospital health-care system. Clin Leadersh Manag Rev 2004 ; 18 : 211-215
 
P.404 掲載の参考文献
1) Fishman N. Antimicrobial stewardship. Am J Med 2006 ; 119 : S53-61
 
2) MacDougall C, et al. Antimicrobial stewardship program in health care systems. Clin Microbiol Rev 2005 ; 18 : 638-656
 
3) Lawton RM, et al. Practices to improve use at 47 US hospitals : the status of the 1997 SHEA/IDSA position paper recommendations. Infect Control Hosp Epidemiol 2000 ; 21 : 256-259
 
4) Craig WA, et al. Hospital use of antimicrobial drugs. Survey at 19 hospitals and results of antimicrobial control program. Ann Int Med 1978 ; 89 : 793-795
 
5) Woodward RS, et al. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987 ; 83 : 817-823
 
6) White AC, et al. Effects requesting prior authorization for selected antimicrobials : Expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997 ; 25 : 230-239
 
7) Gums JG, et al. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by multidisciplinary consult team. Pharmacotherapy 1999 ; 19 : 1369-1377
 
8) Saez-Llorens X, et al. Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities : a lesson from a pediatric institution in a developing country. Pediatr Infect Dis J 2000 ; 19 : 200-206
 
9) Bassetti M, et al. The effect of formulary restriction in the use of antibiotics in an Italian hospital. Eur J Clin Pharmacol 2001 ; 57 : 529-534
 
10) Lemmen SW, et al. Influence of an infectious disease consulting service on quality and costs of antibiotic prescription in a university hospital. Scand J Infect Dis 2001 ; 33 : 219-221
 
11) Bantar C, et al. A hospitalwide intervention program to optimize the quality of antibiotic use : Impact on prescribing practice, antibiotic consumption, cost saving, and bacterial resistance. Clin Infect Dis 2003 ; 37 : 180-186
 
12) Cannon JP, et al. A pharmacist-driven antimicrobial approval program at a Veterans Affairs hospital. Am J Health-Syst Pharm 2003 ; 60 : 1358-1362
 
13) Saizy-Callaert, S et al. Impact of a multidisciplinary approach to the control of antibiotic prescription in a general hospital. J Hosp Infect 2003 ; 53 : 177-182
 
14) Ruttimann S, et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004 ; 38 : 348-356
 
15) Martin C, et al. Results of an antimicrobial control program at a university hospital. Am J Health-Syst Pharm 2005 ; 62 : 732-738
 
16) Ozkurt Z, et al. Changes in antibiotic use, cost and consumption after antibiotic restriction policy applied by infectious disease specialists. Jpn J Infect Dis 2005 ; 58 : 338-343
 
17) Chang MT, et al. The impact of an intensive antimicrobial control program in a Taiwanese medical center. Pharm World Sci 2006 ; 28 : 257-264
 
18) Philmon C, et al. Controlling use of antimicrobials in a community teaching hospital. Infect Control Hosp Epidemiol 2006 ; 27 : 239-244
 
19) Doubilet P, et al. Use and misuse of the term "cost effective" in medicine. NEJM 1986 ; 314 : 253-255
 
20) Paladino JA. Economics of antibiotic use policies. Pharmacotherapy 2004 ; 24 : 232S-238S
 
21) Stone PW, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis 2005 ; 5 : 383-391
 
22) Grundemann H. Mathematical modeling : a tool for hospital infection control. Lancet Infect Dis 2006 ; 6 : 39-45
 
P.407 掲載の参考文献
1) Petrak RM, Sexton DJ, Butera ML, et al. The value of an infectious diseases specialist. Clin Infect Dis 2003 ; 36 : 1013-1017
 
2) Takakura S, Fujihara N, Saito T, et al. Improved clinical outcome of patients with Candida bloodstream infections through direct consultation by infectious diseases physicians in a Japanese university hospital. Infect Control Hosp Epidemiol 2006 ; 27 : 964-968
 
3) Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists : experience with 244 patients. Clin Infect Dis 1998 ; 27 : 478-486
 
4) Gomez J, Conde Cavero SJ, Hernandez Cardona JL, et al. The influence of the opinion of an infectious disease consultant on the appropriateness of antibiotic treatment in a general hospital. J Antimicrob Chemother 1996 ; 38 : 309-314
 
5) Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med 2001 ; 161 : 61-65
 
6) Lemmen SW, Haner H, Kotterik S, et al. Influence of an infectious disease service on antibiotic prescription behavior and selection of multiresistant pathogens. Infection 2000 ; 28 : 384-387
 
7) Banter C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use : Impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003 ; 37 : 180-186
 
8) Lo E, Rezai K, Evans AT, et al. Why don't they listen? Adherence to recommendations of infectious disease consultations. Clin Infect Dis 2004 ; 38 : 1212-1218
 
9) Tenenbaum MJ. Infectious diseases consultative recommendations : if heard, they can be listened to. Clin Infect Dis 2004 ; 38 : 1219-1221
 
10) Deery HG 2nd. Negotiating with administration-or how to get paid for doing hospital epidemiology. Infect Control Hosp Epidemiol 1997 ; 18 : 209-214
 
P.410 掲載の参考文献
1) Polk RE, et al. Antimicrobial management : Cost and resistance. In : Mandell GL, et al eds. Principles and Practice of Infectious Diseases, 6th ed. Pennsylvania : Elsever Churchill Livingstone, 2005 : 611-619
 
2) Delit HT, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis 2007 ; 44 : 159-177
 
3) Ruttimann S, et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004 ; 38 (3) : 348-356
 
4) Lipworth AD, et al. Limiting the emergence of extended-spectrum Beta-lactamase-producing enterobacteriaceae : influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol 2006 ; 27 (3) : 279-286
 
5) Bisson G, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species : risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002 ; 23 (5) : 254-260
 
6) Ho M, et al. Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use. Clin Infect Dis 1996 ; 23 (Suppl 1) : S102-106
 
7) Woodward RS, et al. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987 ; 83 : 817-823
 
8) Rahal JJ, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998 ; 280 (14) : 1233-1237
 
9) Burke JP. Antibiotic resistance-Squeezing the Balloon? JAMA 1998 ; 280 (14) : 1270-1271
 

書評

最近チェックした商品履歴

Loading...